Involvement	O
of	O
a	O
second	O
lymphoid-specific	B-DNA
enhancer	I-DNA
element	I-DNA
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
gene	I-DNA
expression	O
.	O

To	O
determine	O
whether	O
enhancer	B-DNA
elements	I-DNA
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	B-DNA
(	I-DNA
OCTA	I-DNA
)	I-DNA
-nucleotide	I-DNA
motif	I-DNA
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
gene	I-DNA
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	B-DNA
site	I-DNA
for	O
a	O
putative	B-protein
additional	I-protein
lymphoid-specific	I-protein
transcription	I-protein
factor	I-protein
,	O
designated	O
NF-microB	B-protein
,	O
in	O
the	O
murine	B-DNA
IgH	I-DNA
enhancer	I-DNA
.	O

We	O
demonstrate	O
that	O
the	O
NF-microB-binding	B-DNA
site	I-DNA
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	B-DNA
enhancer	I-DNA
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
in	O
cells	O
of	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
but	O
not	O
in	O
nonlymphoid	B-cell_type
cells	I-cell_type
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	B-DNA
site	I-DNA
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	B-DNA
and	O
OCTA	B-DNA
sites	I-DNA
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	B-DNA
or	O
E3	B-DNA
site	I-DNA
in	O
a	O
70-base-pair	B-DNA
fragment	I-DNA
of	O
the	O
IgH	B-DNA
enhancer	I-DNA
that	O
lacks	O
the	O
binding	O
site	O
for	O
OCTA	O
abolished	O
enhancer	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
completely	O
.	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	B-DNA
motif	I-DNA
alone	O
showed	O
no	O
enhancer	O
activity	O
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	B-protein
protein	I-protein
binds	O
to	O
the	O
microB	B-DNA
DNA	I-DNA
motif	I-DNA
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	B-DNA
element	I-DNA
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	B-DNA
element	I-DNA
is	O
essential	O
for	O
its	O
activity	O
.	O

MoLECULAR	NULL
AND	NULL
CELLULAR	NULL
BioLOGYy	NULL
,	NULL
June	NULL
1990	NULL
,	NULL
p.	NULL
3155-3162	NULL
0270-7306/90/063155-08	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

10	NULL
,	NULL
No	NULL
.	NULL

6	NULL
Involvement	NULL
of	NULL
a	NULL
Second	NULL
Lymphoid-Specific	NULL
Enhancer	NULL
Element	NULL
in	NULL
the	NULL
Regulation	NULL
of	NULL
Immunoglobulin	NULL
Heavy-Chain	NULL
Gene	NULL
Expression	NULL
TOWIA	NULL
ARON	NULL
LIBERMANN	NULL
,	NULL
MICHAEL	NULL
LENARDO	NULL
,	NULL
t	NULL
anp	NULL
DAVID	NULL
BALTIMORE*	NULL
Whitehead	NULL
Institute	NULL
for	NULL
Biomedical	NULL
Research	NULL
,	NULL
Cambridge	NULL
,	NULL
Massachusetts	NULL
02142	NULL
,	NULL
and	NULL
Department	NULL
of	NULL
Biology	NULL
,	NULL
Massachusetts	NULL
Institute	NULL
of	NULL
Technology	NULL
,	NULL
Cambridge	NULL
,	NULL
Massachusetts	NULL
02139	NULL
Received	NULL
13	NULL
December	NULL
1989/Accepted	NULL
8	NULL
March	NULL
1990	NULL
To	NULL
determine	NULL
whether	NULL
enhancer	NULL
elements	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
highly	NULL
conserved	NULL
octamer	NULL
(	NULL
OCT	NULL
motif	NULL
are	NULL
important	NULL
for	NULL
lymphoid-specific	NULL
expression	NULL
of	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
(	NULL
IgH	NULL
)	NULL
gene	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
mutating	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
a	NULL
putative	NULL
additional	NULL
lymphoid-specific	NULL
transcription	NULL
factor	NULL
,	NULL
designated	NULL
NF-pB	NULL
,	NULL
in	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
.	NULL

We	NULL
demonstrate	NULL
that	NULL
the	NULL
NF-pB-binding	NULL
site	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
,	NULL
because	NULL
mutation	NULL
of	NULL
the	NULL
mB	NULL
DNA	NULL
motif	NULL
decreased	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
in	NULL
cells	NULL
of	NULL
the	NULL
B-cell	NULL
lineage	NULL
but	NULL
not	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
comparable	NULL
to	NULL
or	NULL
even	NULL
stronger	NULL
than	NULL
the	NULL
effect	NULL
of	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
OCTA	NULL
site	NULL
.	NULL

Moreover	NULL
,	NULL
combined	NULL
mutation	NULL
of	NULL
both	NULL
.B	NULL
and	NULL
OCTA	NULL
sites	NULL
further	NULL
reduced	NULL
enhancer	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
alteration	NULL
of	NULL
either	NULL
the	NULL
pB	NULL
or	NULL
E3	NULL
site	NULL
in	NULL
a	NULL
70-base-pair	NULL
fragment	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
that	NULL
lacks	NULL
the	NULL
binding	NULL
site	NULL
for	NULL
OCTA	NULL
abolished	NULL
enhancer	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
completely	NULL
.	NULL

Nevertheless	NULL
,	NULL
a	NULL
multimer	NULL
of	NULL
the	NULL
mB	NULL
motif	NULL
alone	NULL
showed	NULL
no	NULL
enhancer	NULL
activity	NULL
.	NULL

DNase	NULL
footprinting	NULL
analysis	NULL
corroborated	NULL
the	NULL
functional	NULL
data	NULL
showing	NULL
that	NULL
a	NULL
lymphoid-specific	NULL
protein	NULL
binds	NULL
to	NULL
the	NULL
mB	NULL
DNA	NULL
motif	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
pB	NULL
element	NULL
is	NULL
a	NULL
new	NULL
crucial	NULL
element	NULL
important	NULL
for	NULL
lymphoid-specific	NULL
expression	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
but	NULL
that	NULL
interaction	NULL
with	NULL
another	NULL
enhancer	NULL
element	NULL
is	NULL
essential	NULL
for	NULL
its	NULL
activity	NULL
.	NULL

The	NULL
700-base-pair	NULL
(	NULL
bp	NULL
)	NULL
-long	NULL
immunoglobulin	NULL
heavy-chain	NULL
(	NULL
IgH	NULL
)	NULL
enhancer	NULL
shows	NULL
a	NULL
complex	NULL
modular	NULL
structure	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
overlapping	NULL
positive-acting	NULL
enhancer	NULL
elements	NULL
and	NULL
negative-acting	NULL
elements	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
35	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
these	NULL
elements	NULL
appear	NULL
to	NULL
bind	NULL
ubiquitous	NULL
transcription	NULL
factors	NULL
that	NULL
are	NULL
present	NULL
in	NULL
both	NULL
lymphoid	NULL
and	NULL
nonlymphoid	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
8	NULL
,	NULL
16	NULL
,	NULL
28	NULL
,	NULL
31	NULL
,	NULL
32	NULL
,	NULL
34	NULL
,	NULL
35	NULL
)	NULL
.	NULL

The	NULL
E	NULL
boxes	NULL
El	NULL
,	NULL
E2	NULL
,	NULL
E3	NULL
,	NULL
and	NULL
E4	NULL
represent	NULL
one	NULL
group	NULL
of	NULL
such	NULL
enhancer	NULL
elements	NULL
(	NULL
6	NULL
,	NULL
8	NULL
,	NULL
16	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Mutational	NULL
studies	NULL
have	NULL
suggested	NULL
that	NULL
the	NULL
E-box	NULL
elements	NULL
contribute	NULL
to	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
but	NULL
do	NULL
not	NULL
determine	NULL
lymphoid	NULL
specificity	NULL
(	NULL
13	NULL
,	NULL
16	NULL
,	NULL
27	NULL
,	NULL
42	NULL
)	NULL
.	NULL

An	NULL
additional	NULL
enhancer	NULL
element	NULL
,	NULL
E	NULL
,	NULL
has	NULL
been	NULL
identified	NULL
by	NULL
binding	NULL
of	NULL
a	NULL
protein	NULL
designated	NULL
w-EBP	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Deletion	NULL
analysis	NULL
has	NULL
provided	NULL
evidence	NULL
for	NULL
functional	NULL
importance	NULL
of	NULL
this	NULL
element	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Negative	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
enhancer	NULL
appear	NULL
to	NULL
be	NULL
active	NULL
only	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
and	NULL
thus	NULL
might	NULL
contribute	NULL
to	NULL
lymphoid-specific	NULL
expression	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
(	NULL
30	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Only	NULL
one	NULL
enhancer	NULL
element	NULL
thus	NULL
far	NULL
characterized	NULL
,	NULL
a	NULL
highly	NULL
conserved	NULL
octamer	NULL
(	NULL
OCT	NULL
A	NULL
)	NULL
-nucleotide	NULL
motif	NULL
,	NULL
ATTT	NULL
GCAT	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
confer	NULL
some	NULL
lymphoid	NULL
specificity	NULL
to	NULL
the	NULL
IgH	NULL
gene	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
35	NULL
)	NULL
.	NULL

OCTA	NULL
binds	NULL
a	NULL
variety	NULL
of	NULL
ubiquitous	NULL
and	NULL
cell-restricted	NULL
factors	NULL
(	NULL
17	NULL
,	NULL
33	NULL
,	NULL
39	NULL
)	NULL
.	NULL

The	NULL
Oct-1	NULL
transcription	NULL
factor	NULL
is	NULL
ubiquitously	NULL
expressed	NULL
in	NULL
all	NULL
cell	NULL
types	NULL
(	NULL
15	NULL
,	NULL
39	NULL
,	NULL
41	NULL
)	NULL
,	NULL
whereas	NULL
Oct-2	NULL
expression	NULL
is	NULL
restricted	NULL
to	NULL
B	NULL
cells	NULL
,	NULL
some	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
some	NULL
glial	NULL
cells	NULL
(	NULL
14	NULL
,	NULL
15	NULL
,	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

The	NULL
OCTA-nucleotide	NULL
sequence	NULL
is	NULL
present	NULL
in	NULL
both	NULL
the	NULL
IgH	NULL
promoter	NULL
and	NULL
enhancer	NULL
(	NULL
3	NULL
,	NULL
9	NULL
,	NULL
19	NULL
,	NULL
25	NULL
,	NULL
36	NULL
)	NULL
and	NULL
has	NULL
been	NULL
found	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
other	NULL
genes	NULL
(	NULL
4	NULL
,	NULL
5	NULL
,	NULL
18	NULL
,	NULL
20	NULL
,	NULL
26	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
OCTA	NULL
sequence	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
whole	NULL
IgH	NULL
enhancer	NULL
has	NULL
only	NULL
very	NULL
little	NULL
effect	NULL
on	NULL
its	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
(	NULL
16	NULL
,	NULL
27	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

t	NULL
Present	NULL
address	NULL
:	NULL
Laboratory	NULL
of	NULL
Immunology	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

3155	NULL
of	NULL
additional	NULL
lymphoid-specific	NULL
enhancer	NULL
elements	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
460-bp	NULL
fragment	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
that	NULL
lacks	NULL
the	NULL
OCTA	NULL
sequence	NULL
retains	NULL
substantial	NULL
lymphoid-specific	NULL
enhancer	NULL
activity	NULL
(	NULL
16	NULL
;	NULL
this	NULL
paper	NULL
)	NULL
.	NULL

Araki	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
introduction	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
myeloma	NULL
cells	NULL
into	NULL
murine	NULL
L	NULL
cells	NULL
containing	NULL
the	NULL
human	NULL
IgH	NULL
gene	NULL
leads	NULL
to	NULL
specific	NULL
expression	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
.	NULL

However	NULL
,	NULL
depletion	NULL
of	NULL
OCT	NULL
A-nucleotide-binding	NULL
factors	NULL
from	NULL
myeloma	NULL
nuclear	NULL
extracts	NULL
did	NULL
not	NULL
diminish	NULL
induction	NULL
of	NULL
IgH	NULL
gene	NULL
expression	NULL
in	NULL
L	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
.	NULL

They	NULL
identified	NULL
a	NULL
new	NULL
nuclear	NULL
factor	NULL
that	NULL
showed	NULL
characteristics	NULL
of	NULL
a	NULL
second	NULL
lymphoid-specific	NULL
transcription	NULL
factor	NULL
.	NULL

This	NULL
factor	NULL
has	NULL
been	NULL
purified	NULL
from	NULL
a	NULL
murine	NULL
myeloma	NULL
and	NULL
binds	NULL
to	NULL
the	NULL
sequence	NULL
S-TATTTTAGGAAGCAAA-3	NULL
'	NULL
in	NULL
the	NULL
human	NULL
IgH	NULL
enhancer	NULL
just	NULL
downstream	NULL
of	NULL
the	NULL
E3	NULL
motif	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
IgH	NULL
enhancer	NULL
contains	NULL
a	NULL
similar	NULL
but	NULL
not	NULL
identical	NULL
sequence	NULL
at	NULL
the	NULL
same	NULL
location	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

The	NULL
purified	NULL
factor	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
expression	NULL
in	NULL
the	NULL
human	NULL
IgH	NULL
gene	NULL
in	NULL
murine	NULL
L	NULL
cells	NULL
and	NULL
thus	NULL
may	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
IgH	NULL
gene	NULL
expression	NULL
(	NULL
1	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
functional	NULL
role	NULL
of	NULL
this	NULL
new	NULL
factor	NULL
,	NULL
designated	NULL
NF-pB	NULL
in	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
introduced	NULL
mutations	NULL
into	NULL
the	NULL
homologous	NULL
NF-uB-	NULL
and	NULL
OCTA-binding	NULL
sites	NULL
of	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
.	NULL

We	NULL
tested	NULL
whether	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
wB	NULL
element	NULL
is	NULL
functionally	NULL
comparable	NULL
to	NULL
the	NULL
human	NULL
IgH	NULL
enhancer	NULL
element	NULL
and	NULL
whether	NULL
the	NULL
B	NULL
motif	NULL
could	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
lymphoid-specific	NULL
expression	NULL
of	NULL
an	NULL
OCT	NULL
A-deleted	NULL
IgH	NULL
enhancer	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
mutation	NULL
of	NULL
wB	NULL
reduces	NULL
activity	NULL
of	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
in	NULL
pre-B	NULL
,	NULL
mature	NULL
B	NULL
,	NULL
and	NULL
plasma	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
.	NULL

We	NULL
have	NULL
narrowed	NULL
down	NULL
the	NULL
lymphoid-specific	NULL
element	NULL
to	NULL
a	NULL
70-bp	NULL
fragment	NULL
that	NULL
contains	NULL
B	NULL
and	NULL
E3	NULL
but	NULL
not	NULL
OCTA	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
other	NULL
enhancer	NULL
elements	NULL
,	NULL
no	NULL
intrinsic	NULL
enhancer	NULL
activity	NULL
was	NULL
detected	NULL
with	NULL
the	NULL
wB	NULL
motif	NULL
by	NULL
itself	NULL
,	NULL
suggesting	NULL
a	NULL
necessity	NULL
for	NULL
interaction	NULL
with	NULL
another	NULL
enhancer	NULL
element	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
B	NULL
together	NULL
with	NULL
OCTA	NULL
3156	NULL
LIBERMANN	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
TATT	NULL
A	NULL
4	NULL
GTCATGTGGC	NULL
ATTTGCAT	NULL
vDJ	NULL
Pk	NULL
A	NULL
/	NULL
EcoRt	NULL
C	NULL
14-0	NULL
-	NULL
te	NULL
RRC	NULL
E2	NULL
£4	NULL
Octo	NULL
TAT	NULL
T	NULL
TGGGGAAGGG	NULL
Wt	NULL
TCA	NULL
B	NULL
B	NULL
Sall	NULL
TATA	NULL
CAT	NULL
|	NULL
L	NULL
r	NULL
“	NULL
-56	NULL
0	NULL
+4107	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Structures	NULL
of	NULL
IgH	NULL
enhancer	NULL
constructs	NULL
used	NULL
for	NULL
transfections	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Schematic	NULL
diagram	NULL
of	NULL
mutations	NULL
introduced	NULL
into	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
.	NULL

Filled	NULL
symbols	NULL
represent	NULL
the	NULL
various	NULL
transcription	NULL
factor-binding	NULL
sites	NULL
.	NULL

The	NULL
circle	NULL
indicates	NULL
the	NULL
OCTA	NULL
motif	NULL
;	NULL
boxes	NULL
show	NULL
the	NULL
different	NULL
E-box	NULL
sites	NULL
;	NULL
the	NULL
diamond	NULL
indicates	NULL
the	NULL
1B	NULL
DNA	NULL
motif	NULL
.	NULL

The	NULL
wild-type	NULL
sequences	NULL
of	NULL
E3	NULL
,	NULL
B	NULL
,	NULL
and	NULL
OCTA	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
expansions	NULL
above	NULL
and	NULL
below	NULL
the	NULL
diagram	NULL
.	NULL

Arrows	NULL
point	NULL
to	NULL
the	NULL
nucleotides	NULL
introduced	NULL
by	NULL
mutations	NULL
into	NULL
the	NULL
wild-type	NULL
sequence	NULL
.	NULL

Open	NULL
boxes	NULL
represent	NULL
exons	NULL
for	NULL
the	NULL
constant	NULL
and	NULL
variable	NULL
regions	NULL
;	NULL
the	NULL
thin	NULL
line	NULL
indicates	NULL
the	NULL
intron	NULL
.	NULL

The	NULL
enhancer	NULL
fragment	NULL
referred	NULL
to	NULL
as	NULL
700	NULL
extends	NULL
between	NULL
the	NULL
Xbal	NULL
and	NULL
EcoRI	NULL
sites	NULL
.	NULL

1300	NULL
extends	NULL
between	NULL
the	NULL
Pvull	NULL
and	NULL
EcoRI	NULL
sites	NULL
.	NULL

The	NULL
segment	NULL
referred	NULL
to	NULL
as	NULL
1460	NULL
extends	NULL
between	NULL
the	NULL
Xbal	NULL
and	NULL
Alul	NULL
sites	NULL
,	NULL
and	NULL
fragment	NULL
170	NULL
extends	NULL
between	NULL
the	NULL
Pvull	NULL
and	NULL
Alul	NULL
sites	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
insertion	NULL
site	NULL
(	NULL
Sall	NULL
)	NULL
for	NULL
enhancer	NULL
fragments	NULL
into	NULL
the	NULL
c-fos	NULL
promoter	NULL
AS6/CAT	NULL
fusion	NULL
plasmid	NULL
56	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

The	NULL
B	NULL
orientation	NULL
is	NULL
the	NULL
reverse	NULL
orientation	NULL
of	NULL
the	NULL
enhancer	NULL
fragments	NULL
shown	NULL
in	NULL
panel	NULL
A.	NULL
may	NULL
determine	NULL
most	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
expression	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
and	NULL
demonstrate	NULL
that	NULL
the	NULL
uB	NULL
DNA	NULL
motif	NULL
binds	NULL
a	NULL
lymphoid-specific	NULL
factor	NULL
or	NULL
factors	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
.	NULL

$	NULL
194	NULL
(	NULL
murine	NULL
myeloma	NULL
)	NULL
,	NULL
NIH	NULL
3T3	NULL
(	NULL
murine	NULL
fibroblast	NULL
)	NULL
,	NULL
HeLa	NULL
(	NULL
human	NULL
cervical	NULL
carcinoma	NULL
)	NULL
,	NULL
U-C12:6	NULL
(	NULL
human	NULL
glioma	NULL
)	NULL
,	NULL
and	NULL
EJ	NULL
(	NULL
human	NULL
bladder	NULL
carcinoma	NULL
)	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

PD31	NULL
(	NULL
murine	NULL
Abelson	NULL
murine	NULL
leukemia	NULL
virus-transformed	NULL
pre-B	NULL
cell	NULL
line	NULL
)	NULL
and	NULL
BJAB	NULL
(	NULL
human	NULL
B-cell	NULL
lymphoma	NULL
)	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
50	NULL
uM	NULL
2-mercaptoeth-anol	NULL
.	NULL

HAFTL	NULL
(	NULL
murine	NULL
Harvey	NULL
v-ras-transformed	NULL
early	NULL
pre-B-cell	NULL
line	NULL
)	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
15	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
50	NULL
M	NULL
2-mercaptoeth-anol	NULL
.	NULL

32D	NULL
(	NULL
murine	NULL
early	NULL
myeloid	NULL
cell	NULL
line	NULL
)	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
10	NULL
%	NULL
conditioned	NULL
medium	NULL
from	NULL
WEHI	NULL
3	NULL
cells	NULL
.	NULL

Nuclear	NULL
extracts	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
7	NULL
)	NULL
.	NULL

Nuclear	NULL
extract	NULL
from	NULL
32D	NULL
cells	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Stephen	NULL
Smale	NULL
(	NULL
Whitehead	NULL
Institute	NULL
)	NULL
.	NULL

Heparin-agarose	NULL
fractions	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
HeLa	NULL
and	NULL
BJAB	NULL
cells	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Mark	NULL
Kamps	NULL
(	NULL
Whitehead	NULL
Institute	NULL
)	NULL
.	NULL

Enhancer/chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
plasmid	NULL
construction	NULL
.	NULL

The	NULL
X/hol-linkered	NULL
700-bp	NULL
IgH	NULL
enhancer	NULL
and	NULL
fragments	NULL
thereof	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
Salil	NULL
site	NULL
in	NULL
the	NULL
A-56-c-fos-CAT	NULL
plasmid	NULL
described	NULL
by	NULL
Gilman	NULL
et	NULL
al	NULL
.	NULL

(	NULL
10	NULL
)	NULL
and	NULL
Lenardo	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
in	NULL
the	NULL
B	NULL
orientation	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

A	NULL
synthetic	NULL
34-bp	NULL
wB	NULL
oligonucleotide	NULL
5'-TCGAGCAAGGCTATTTGGGGAAGGGAAAATAAAG-3	NULL
'	NULL
3'-CGTTCCGATAAACCCCTTCCCTTTTATTTCAGCT-5	NULL
'	NULL
containing	NULL
Sall	NULL
and	NULL
Xhol	NULL
ends	NULL
was	NULL
inserted	NULL
as	NULL
a	NULL
monomer	NULL
,	NULL
dimer	NULL
,	NULL
and	NULL
tetramer	NULL
into	NULL
the	NULL
Sall	NULL
site	NULL
in	NULL
the	NULL
AS6-c-fos-CAT	NULL
plasmid	NULL
(	NULL
10	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
.	NULL

Plasmids	NULL
containing	NULL
mutations	NULL
in	NULL
either	NULL
OCTA	NULL
or	NULL
E3	NULL
were	NULL
derived	NULL
from	NULL
plasmids	NULL
described	NULL
by	NULL
Lenardo	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
.	NULL

Specific	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
three	NULL
nucleotides	NULL
in	NULL
the	NULL
B	NULL
DNA	NULL
motif	NULL
of	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
between	NULL
positions	NULL
414	NULL
and	NULL
427	NULL
was	NULL
introduced	NULL
by	NULL
the	NULL
gapped/heteroduplex	NULL
method	NULL
(	NULL
40	NULL
)	NULL
,	NULL
using	NULL
an	NULL
oligonucleotide	NULL
S-GTGGCAAGGCTATTTGTCAAAGGGAAAATAA-3	NULL
'	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

DNA	NULL
transfection	NULL
assays	NULL
.	NULL

Transfections	NULL
of	NULL
cells	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
IgH	NULL
enhancer/A56	NULL
plasmid	NULL
,	NULL
using	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
16	NULL
,	NULL
29	NULL
)	NULL
.	NULL

NIH	NULL
3T3	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
the	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
method	NULL
(	NULL
16	NULL
,	NULL
29	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
30	NULL
to	NULL
100	NULL
ug	NULL
of	NULL
heat-inactivated	NULL
(	NULL
16	NULL
)	NULL
cell	NULL
extract	NULL
was	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
11	NULL
)	NULL
in	NULL
a	NULL
1-h	NULL
incubation	NULL
at	NULL
37°C	NULL
.	NULL

Transfections	NULL
for	NULL
every	NULL
construct	NULL
were	NULL
performed	NULL
independently	NULL
in	NULL
duplicate	NULL
and	NULL
repeated	NULL
two	NULL
to	NULL
four	NULL
times	NULL
.	NULL

Samples	NULL
were	NULL
analyzed	NULL
by	NULL
thin-layer	NULL
chromatography	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
acetylated	NULL
chloramphenicol	NULL
was	NULL
determined	NULL
by	NULL
cutting	NULL
out	NULL
nonacetylated	NULL
and	NULL
acetylated	NULL
forms	NULL
of	NULL
chloramphenicol	NULL
and	NULL
measuring	NULL
the	NULL
amount	NULL
of	NULL
radioactivity	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
analysis	NULL
.	NULL

460/A56	NULL
and	NULL
L460	NULL
uB_-/	NULL
A56	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
were	NULL
linearized	NULL
with	NULL
HindIII	NULL
,	NULL
dephospho-rylated	NULL
,	NULL
and	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
y-*P	NULL
]	NULL
JATP	NULL
and	NULL
T4	NULL
polynucle-otide	NULL
kinase	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
noncoding	NULL
strand	NULL
.	NULL

After	NULL
digestion	NULL
with	NULL
Sal	NULL
,	NULL
end-labeled	NULL
p460	NULL
and	NULL
1460	NULL
B-HindlII-Sall	NULL
fragments	NULL
were	NULL
gel	NULL
purified	NULL
.	NULL

DNase	NULL
I	NULL
footprinting	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
Jones	NULL
et	NULL
al	NULL
.	NULL

(	NULL
12	NULL
)	NULL
,	NULL
using	NULL
0.3	NULL
to	NULL
0.8	NULL
ng	NULL
of	NULL
end-labeled	NULL
IgH	NULL
enhancer	NULL
fragments	NULL
(	NULL
5,000	NULL
cpm	NULL
)	NULL
,	NULL
20	NULL
ug	NULL
of	NULL
total	NULL
nuclear	NULL
extract	NULL
,	NULL
3	NULL
ug	NULL
of	NULL
heparin-agarose-purified	NULL
nuclear	NULL
extract	NULL
,	NULL
or	NULL
no	NULL
protein	NULL
,	NULL
1	NULL
g	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
for	NULL
total	NULL
nuclear	NULL
extract	NULL
and	NULL
0.2	NULL
pug	NULL
for	NULL
heparin-agarose	NULL
fractions	NULL
,	NULL
and	NULL
2	NULL
%	NULL
polyvinyl	NULL
alcohol	NULL
in	NULL
50	NULL
pl	NULL
.	NULL

A	NULL
ladder	NULL
of	NULL
G+A	NULL
Maxam-Gilbert	NULL
(	NULL
21	NULL
)	NULL
sequence	NULL
reaction	NULL
of	NULL
the	NULL
labeled	NULL
IgH	NULL
enhancer	NULL
fragments	NULL
was	NULL
run	NULL
as	NULL
a	NULL
marker	NULL
.	NULL

RESULTS	NULL
Lymphoid-specific	NULL
transcription	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
is	NULL
for	NULL
the	NULL
most	NULL
part	NULL
dependent	NULL
on	NULL
two	NULL
enhancer	NULL
elements	NULL
,	NULL
OCTA	NULL
and	NULL
pB	NULL
.	NULL

The	NULL
pB	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
was	NULL
identified	NULL
as	NULL
a	NULL
putative	NULL
lymphoid-specific	NULL
enhancer	NULL
element	NULL
(	NULL
1	NULL
)	NULL
along	NULL
with	NULL
the	NULL
OCTA	NULL
motif	NULL
(	NULL
16	NULL
)	NULL
.	NULL

To	NULL
study	NULL
these	NULL
enhancer	NULL
elements	NULL
,	NULL
we	NULL
introduced	NULL
mutations	NULL
in	NULL
the	NULL
B	NULL
,	NULL
OCTA	NULL
and	NULL
E3	NULL
sites	NULL
by	NULL
using	NULL
synthetic	NULL
oligonucleotides	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Wild-type	NULL
and	NULL
mutant	NULL
IgH	NULL
enhancers	NULL
as	NULL
well	NULL
as	NULL
fragments	NULL
thereof	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
were	NULL
cloned	NULL
into	NULL
the	NULL
Sa/I	NULL
site	NULL
just	NULL
upstream	NULL
of	NULL
the	NULL
truncated	NULL
c-fos	NULL
promoter	NULL
of	NULL
the	NULL
AS6	NULL
plasmid	NULL
(	NULL
10	NULL
,	NULL
16	NULL
)	NULL
in	NULL
the	NULL
B	NULL
orientation	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

We	NULL
measured	NULL
enhancer	NULL
activity	NULL
as	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
different	NULL
enhancer	NULL
constructs	NULL
to	NULL
induce	NULL
transcription	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
after	NULL
transient	NULL
expression	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

The	NULL
full-length	NULL
700-bp	NULL
IgH	NULL
enhancer	NULL
(	NULL
700	NULL
WT	NULL
)	NULL
stimulated	NULL
transcription	NULL
50-fold	NULL
in	NULL
$	NULL
194	NULL
myeloma	NULL
cells	NULL
and	NULL
20-fold	NULL
in	NULL
PD31	NULL
pre-B	NULL
lymphoid	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
1	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
level	NULL
of	NULL
the	NULL
control	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
14	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
activities	NULL
of	NULL
mutant	NULL
enhancers	NULL
were	NULL
compared	NULL
with	NULL
the	NULL
level	NULL
of	NULL
either	NULL
the	NULL
full-length	NULL
or	NULL
partial	NULL
fragments	NULL
of	NULL
the	NULL
wild-type	NULL
700-bp	NULL
IgH	NULL
enhancer	NULL
(	NULL
700	NULL
WT	NULL
)	NULL
Vor	NULL
.	NULL

10	NULL
,	NULL
1990	NULL
LYMPHOID-SPECIFIC	NULL
ENHANCER	NULL
ELEMENT	NULL
IN	NULL
IgH	NULL
GENE	NULL
3157	NULL
0	NULL
100	NULL
200	NULL
300	NULL
400	NULL
500	NULL
600	NULL
700	NULL
bp	NULL
;	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
I	NULL
E1	NULL
E2	NULL
E3	NULL
E4	NULL
OCTA	NULL
%	NULL
Relative	NULL
Cat	NULL
Activity	NULL
N	NULL
{	NULL
eeB	NULL
NC	NULL
$	NULL
194	NULL
,	NULL
PD3H	NULL
1	NULL
.	NULL

4	NULL
700	NULL
WT	NULL
0-10	NULL
{	NULL
o-	NULL
100	NULL
|	NULL
100	NULL
2	NULL
v	NULL
700	NULL
0~	NULL
-1-106	NULL
{	NULL
e	NULL
58	NULL
B9	NULL
3	NULL
.	NULL

__	NULL
4700	NULL
aB	NULL
45	NULL
|	NULL
44	NULL
4	NULL
.	NULL

-	NULL
4700	NULL
0	NULL
aB	NULL
``	NULL
15	NULL
|_	NULL
25	NULL
5	NULL
4	NULL
300	NULL
WT	NULL
841	NULL
|	NULL
318	NULL
6	NULL
.	NULL

4	NULL
300	NULL
0	NULL
``	NULL
00-lo	NULL
--	NULL
--	NULL
-	NULL
515	NULL
|	NULL
139	NULL
7	NULL
.	NULL

_-	NULL
4300uB8~	NULL
N+	NULL
--	NULL
{	NULL
1O	NULL
--	NULL
--	NULL
-	NULL
396	NULL
|	NULL
30	NULL
8	NULL
.	NULL

4	NULL
300	NULL
0~uB_	NULL
N+	NULL
--	NULL
Jo	NULL
--	NULL
--	NULL
-	NULL
t45	NULL
|	NULL
1	NULL
9	NULL
-_	NULL
4460	NULL
WT	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
tH-IlO	NULL
13.5	NULL
|	NULL
nad	NULL
.	NULL

10	NULL
.	NULL

__	NULL
4460	NULL
48	NULL
``	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
IG¥	NULL
20	NULL
|	NULL
na	NULL
.	NULL

11	NULL
.	NULL

4	NULL
70	NULL
WT	NULL
00-	NULL
105	NULL
|	NULL
nd	NULL
.	NULL

12	NULL
70	NULL
E3~	NULL
No-	NULL
19	NULL
|	NULL
na	NULL
.	NULL

13	NULL
.	NULL

470	NULL
uB-	NULL
LDL	NULL
a	NULL
1.8	NULL
|	NULL
nad	NULL
.	NULL

14	NULL
.	NULL

ENH	NULL
~	NULL
20|	NULL
50	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Relative	NULL
activities	NULL
of	NULL
IgH	NULL
enhancer	NULL
fragments	NULL
and	NULL
mutations	NULL
in	NULL
$	NULL
194	NULL
myeloma	NULL
and	NULL
PD31	NULL
pre-B	NULL
cells	NULL
.	NULL

Symbols	NULL
indicate	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
different	NULL
enhancer	NULL
elements	NULL
,	NULL
analogous	NULL
to	NULL
those	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
.	NULL

Empty	NULL
symbols	NULL
represent	NULL
wild-type	NULL
configurations	NULL
;	NULL
solid	NULL
boxes	NULL
indicate	NULL
mutated	NULL
sites	NULL
as	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
.	NULL

Deletions	NULL
are	NULL
given	NULL
by	NULL
the	NULL
loss	NULL
of	NULL
part	NULL
of	NULL
the	NULL
thin	NULL
line	NULL
.	NULL

Half	NULL
of	NULL
a	NULL
box	NULL
indicates	NULL
deletion	NULL
starting	NULL
in	NULL
the	NULL
middle	NULL
of	NULL
the	NULL
E2	NULL
site	NULL
.	NULL

The	NULL
CAT	NULL
activity	NULL
of	NULL
each	NULL
construct	NULL
transfected	NULL
into	NULL
either	NULL
$	NULL
194	NULL
or	NULL
PD31	NULL
cells	NULL
is	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
700	NULL
IgH	NULL
enhancer/CAT	NULL
construct	NULL
in	NULL
line	NULL
1	NULL
.	NULL

CAT	NULL
values	NULL
are	NULL
averages	NULL
derived	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
of	NULL
two	NULL
independent	NULL
transfections	NULL
.	NULL

Repeated	NULL
experiments	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
with	NULL
deviations	NULL
of	NULL
less	NULL
than	NULL
20	NULL
%	NULL
compared	NULL
with	NULL
the	NULL
values	NULL
given	NULL
.	NULL

ENH~	NULL
(	NULL
line	NULL
14	NULL
)	NULL
indicates	NULL
the	NULL
enhancerless	NULL
A56	NULL
background	NULL
plasmid	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

The	NULL
3	NULL
'	NULL
300-bp	NULL
part	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
(	NULL
L300	NULL
WT	NULL
)	NULL
,	NULL
which	NULL
lacks	NULL
El	NULL
and	NULL
E2	NULL
,	NULL
expressed	NULL
8.4-	NULL
and	NULL
3.2-times-higher	NULL
CAT	NULL
activity	NULL
than	NULL
did	NULL
1700	NULL
WT	NULL
in	NULL
$	NULL
194	NULL
and	NULL
PD31	NULL
cells	NULL
,	NULL
respectively	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
A	NULL
orientation	NULL
(	NULL
16	NULL
)	NULL
,	NULL
700	NULL
expressed	NULL
much	NULL
higher	NULL
activity	NULL
than	NULL
did	NULL
1300	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mutation	NULL
in	NULL
the	NULL
OCTA	NULL
motif	NULL
within	NULL
L700	NULL
(	NULL
700	NULL
OT	NULL
)	NULL
reduced	NULL
CAT	NULL
activity	NULL
in	NULL
$	NULL
194	NULL
myeloma	NULL
cells	NULL
by	NULL
only	NULL
about	NULL
40	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
but	NULL
had	NULL
a	NULL
very	NULL
small	NULL
effect	NULL
in	NULL
the	NULL
pre-B-cell	NULL
line	NULL
PD31	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
2	NULL
;	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
suggesting	NULL
the	NULL
presence	NULL
of	NULL
lymphoid-specific	NULL
enhancer	NULL
elements	NULL
in	NULL
1700	NULL
independent	NULL
of	NULL
OCTA	NULL
(	NULL
16	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
wB	NULL
DNA	NULL
motif	NULL
on	NULL
enhancer	NULL
activity	NULL
.	NULL

Mutation	NULL
in	NULL
the	NULL
B	NULL
motif	NULL
within	NULL
700	NULL
(	NULL
1.700	NULL
wB~	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
decrease	NULL
of	NULL
about	NULL
55	NULL
%	NULL
in	NULL
both	NULL
$	NULL
194	NULL
and	NULL
PD31	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
3	NULL
;	NULL
Fig	NULL
.	NULL

3A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
mutation	NULL
in	NULL
the	NULL
wB	NULL
DNA	NULL
motif	NULL
had	NULL
an	NULL
even	NULL
more	NULL
drastic	NULL
effect	NULL
on	NULL
transcription	NULL
of	NULL
700	NULL
in	NULL
a	NULL
very	NULL
early	NULL
pre-B-cell	NULL
line	NULL
,	NULL
HAFTL	NULL
,	NULL
in	NULL
which	NULL
the	NULL
wB~	NULL
mutation	NULL
reduced	NULL
CAT	NULL
activity	NULL
by	NULL
more	NULL
than	NULL
80	NULL
%	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
the	NULL
OCTA	NULL
mutation	NULL
had	NULL
only	NULL
a	NULL
slight	NULL
effect	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
wB	NULL
site	NULL
encodes	NULL
an	NULL
IgH	NULL
enhancer	NULL
element	NULL
that	NULL
may	NULL
be	NULL
more	NULL
important	NULL
for	NULL
transcriptional	NULL
activity	NULL
in	NULL
cells	NULL
early	NULL
in	NULL
the	NULL
B-lymphoid	NULL
lineage	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
OCTA	NULL
appears	NULL
to	NULL
play	NULL
a	NULL
larger	NULL
role	NULL
in	NULL
the	NULL
more	NULL
mature	NULL
cells	NULL
.	NULL

Strikingly	NULL
,	NULL
combined	NULL
mutation	NULL
of	NULL
both	NULL
the	NULL
mB	NULL
and	NULL
OCTA	NULL
motifs	NULL
(	NULL
700	NULL
O~	NULL
BT	NULL
)	NULL
led	NULL
to	NULL
severe	NULL
decreases	NULL
in	NULL
CAT	NULL
activity	NULL
in	NULL
all	NULL
types	NULL
of	NULL
B	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
4	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

These	NULL
effects	NULL
were	NULL
more	NULL
dramatic	NULL
than	NULL
either	NULL
mutation	NULL
alone	NULL
,	NULL
reflecting	NULL
a	NULL
requirement	NULL
for	NULL
both	NULL
wB	NULL
and	NULL
OCTA	NULL
.	NULL

In	NULL
$	NULL
194	NULL
and	NULL
PD31	NULL
cells	NULL
,	NULL
residual	NULL
enhancer	NULL
activities	NULL
of	NULL
15	NULL
and	NULL
25	NULL
%	NULL
of	NULL
700	NULL
WT	NULL
activity	NULL
,	NULL
respectively	NULL
,	NULL
were	NULL
observed	NULL
even	NULL
when	NULL
both	NULL
B	NULL
and	NULL
OCTA	NULL
sites	NULL
were	NULL
mutated	NULL
.	NULL

Thus	NULL
,	NULL
further	NULL
enhancer	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
must	NULL
be	NULL
active	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
mutating	NULL
the	NULL
OCTA	NULL
or	NULL
pB	NULL
motif	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
300	NULL
enhancer	NULL
fragment	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
from	NULL
the	NULL
Pvull	NULL
to	NULL
EcoRI	NULL
sites	NULL
)	NULL
,	NULL
which	NULL
lacks	NULL
E1	NULL
,	NULL
E2	NULL
,	NULL
and	NULL
other	NULL
putative	NULL
upstream	NULL
elements	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lines	NULL
5	NULL
to	NULL
8	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

As	NULL
for	NULL
1700	NULL
,	NULL
mutations	NULL
in	NULL
wB	NULL
always	NULL
had	NULL
a	NULL
stronger	NULL
effect	NULL
on	NULL
transcription	NULL
than	NULL
did	NULL
mutations	NULL
in	NULL
OCTA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lines	NULL
5	NULL
to	NULL
7	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

This	NULL
was	NULL
particularly	NULL
evident	NULL
in	NULL
PD31	NULL
cells	NULL
,	NULL
in	NULL
which	NULL
mutation	NULL
in	NULL
B	NULL
decreased	NULL
CAT	NULL
activity	NULL
by	NULL
more	NULL
than	NULL
10-fold	NULL
,	NULL
whereas	NULL
mutation	NULL
in	NULL
OCTA	NULL
led	NULL
to	NULL
only	NULL
a	NULL
2-fold	NULL
decrease	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Double	NULL
mutation	NULL
in	NULL
both	NULL
wB	NULL
and	NULL
OCTA	NULL
within	NULL
300	NULL
,	NULL
similar	NULL
to	NULL
700	NULL
,	NULL
caused	NULL
greater	NULL
decreases	NULL
in	NULL
transcription	NULL
than	NULL
either	NULL
alone	NULL
in	NULL
$	NULL
194	NULL
,	NULL
PD31	NULL
,	NULL
and	NULL
HAFTL	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
8	NULL
;	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
the	NULL
functional	NULL
consequence	NULL
of	NULL
the	NULL
removal	NULL
of	NULL
the	NULL
whole	NULL
3	NULL
'	NULL
end	NULL
of	NULL
the	NULL
enhancer	NULL
,	NULL
containing	NULL
both	NULL
E4	NULL
and	NULL
OCTA	NULL
,	NULL
we	NULL
created	NULL
p460	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lines	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

This	NULL
deletion	NULL
led	NULL
to	NULL
a	NULL
drastic	NULL
reduction	NULL
of	NULL
transcription	NULL
to	NULL
13.5	NULL
%	NULL
of	NULL
the	NULL
level	NULL
of	NULL
1700	NULL
WT	NULL
in	NULL
$	NULL
194	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
important	NULL
sites	NULL
other	NULL
than	NULL
OCTA	NULL
are	NULL
removed	NULL
by	NULL
this	NULL
deletion	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
line	NULL
9	NULL
)	NULL
.	NULL

Alterations	NULL
in	NULL
the	NULL
wB	NULL
motif	NULL
within	NULL
this	NULL
construct	NULL
abrogated	NULL
all	NULL
enhancer	NULL
activity	NULL
in	NULL
$	NULL
194	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lines	NULL
9	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
even	NULL
though	NULL
1460	NULL
contains	NULL
several	NULL
E-box	NULL
elements	NULL
(	NULL
El	NULL
,	NULL
E2	NULL
,	NULL
and	NULL
E3	NULL
)	NULL
,	NULL
mutation	NULL
of	NULL
mB	NULL
alone	NULL
drastically	NULL
reduces	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
1460	NULL
.	NULL

This	NULL
context	NULL
illustrates	NULL
most	NULL
vividly	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
pB	NULL
site	NULL
for	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

mB	NULL
needs	NULL
a	NULL
second	NULL
enhancer	NULL
element	NULL
for	NULL
its	NULL
function	NULL
.	NULL

Because	NULL
alteration	NULL
of	NULL
the	NULL
B	NULL
site	NULL
in	NULL
1460	NULL
suggested	NULL
that	NULL
this	NULL
site	NULL
might	NULL
be	NULL
the	NULL
crucial	NULL
enhancer	NULL
element	NULL
in	NULL
this	NULL
fragment	NULL
,	NULL
we	NULL
made	NULL
further	NULL
truncations	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

70	NULL
WT	NULL
,	NULL
containing	NULL
only	NULL
the	NULL
E3	NULL
and	NULL
B	NULL
motifs	NULL
as	NULL
identified	NULL
enhancer	NULL
elements	NULL
but	NULL
lacking	NULL
El	NULL
,	NULL
E2	NULL
,	NULL
E4	NULL
,	NULL
and	NULL
OCTA	NULL
,	NULL
expressed	NULL
transcriptional	NULL
activity	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
460	NULL
in	NULL
$	NULL
194	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lines	NULL
9	NULL
and	NULL
11	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
the	NULL
E3	NULL
or	NULL
wB	NULL
site	NULL
abolished	NULL
enhancer	NULL
activity	NULL
of	NULL
p70	NULL
in	NULL
$	NULL
194	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lines	NULL
11	NULL
to	NULL
14	NULL
)	NULL
.	NULL

Because	NULL
alteration	NULL
of	NULL
E3	NULL
had	NULL
the	NULL
same	NULL
effect	NULL
as	NULL
3158	NULL
LIBERMANN	NULL
ET	NULL
AL	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

3	NULL
S	NULL
8	NULL
8	NULL
%	NULL
RELATIVE	NULL
CAT	NULL
ACTIVITY	NULL
3	NULL
,	NULL
Po	NULL
o	NULL
ej	NULL
E	NULL
700	NULL
é	NULL
100	NULL
|-	NULL
|	NULL
w	NULL
q	NULL
80._	NULL
|	NULL
&	NULL
S	NULL
sol-	NULL
|	NULL
Ww	NULL
S	NULL
40	NULL
}	NULL
|	NULL
S	NULL
3:4	NULL
20	NULL
-	NULL
~	NULL
&	NULL
&	NULL
o	NULL
4	NULL
£22272	NULL
crrrz	NULL
wT	NULL
-	NULL
O~	NULL
-	NULL
287	NULL
O~LB	NULL
``	NULL
ENH~	NULL
wT	NULL
O7	NULL
287	NULL
ENH~	NULL
t	NULL
4	NULL
700	NULL
4	NULL
300	NULL
&	NULL
E	NULL
100	NULL
-	NULL
m	NULL
&	NULL
S	NULL
go-	NULL
|	NULL
h	NULL
a	NULL
60	NULL
-	NULL
|	NULL
w	NULL
§	NULL
40	NULL
s	NULL
331	NULL
20	NULL
|-	NULL
z	NULL
|	NULL
®	NULL
,	NULL
l	NULL
E	NULL
)	NULL
#	NULL
WT	NULL
0	NULL
-	NULL
2B	NULL
``	NULL
0	NULL
ENH~	NULL
wT	NULL
0	NULL
LB	NULL
``	NULL
ENH~	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Effects	NULL
of	NULL
mutations	NULL
on	NULL
IgH	NULL
enhancer	NULL
transcription	NULL
rate	NULL
.	NULL

The	NULL
700	NULL
and	NULL
300	NULL
IgH	NULL
enhancers	NULL
with	NULL
mutations	NULL
in	NULL
either	NULL
OCTA	NULL
(	NULL
07	NULL
)	NULL
or	NULL
wB	NULL
(	NULL
BT	NULL
)	NULL
were	NULL
tested	NULL
in	NULL
$	NULL
194	NULL
myeloma	NULL
(	NULL
A	NULL
)	NULL
,	NULL
PD31	NULL
pre-B	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
HAFTL	NULL
early	NULL
pre-B	NULL
(	NULL
C	NULL
)	NULL
cells	NULL
.	NULL

In	NULL
each	NULL
experiment	NULL
,	NULL
each	NULL
value	NULL
is	NULL
the	NULL
average	NULL
of	NULL
two	NULL
representative	NULL
independent	NULL
transfections	NULL
;	NULL
repeated	NULL
experiments	NULL
gave	NULL
similar	NULL
results	NULL
in	NULL
which	NULL
the	NULL
standard	NULL
deviations	NULL
were	NULL
less	NULL
than	NULL
20	NULL
%	NULL
compared	NULL
with	NULL
the	NULL
values	NULL
given	NULL
.	NULL

Absolute	NULL
percent	NULL
conversions	NULL
of	NULL
chloramphenicol	NULL
to	NULL
acetylated	NULL
forms	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
700	NULL
WT	NULL
,	NULL
7.6	NULL
%	NULL
for	NULL
$	NULL
194	NULL
,	NULL
4.4	NULL
%	NULL
for	NULL
PD31	NULL
,	NULL
and	NULL
1.8	NULL
%	NULL
for	NULL
HAFTL	NULL
;	NULL
£300	NULL
WT	NULL
,	NULL
63.8	NULL
%	NULL
for	NULL
$	NULL
194	NULL
,	NULL
14	NULL
%	NULL
for	NULL
PD31	NULL
,	NULL
and	NULL
2.4	NULL
%	NULL
for	NULL
HAFTL	NULL
(	NULL
the	NULL
CAT	NULL
assays	NULL
with	NULL
300	NULL
were	NULL
repeated	NULL
for	NULL
$	NULL
194	NULL
cells	NULL
with	NULL
less	NULL
cell	NULL
extract	NULL
in	NULL
order	NULL
to	NULL
keep	NULL
a	NULL
linear	NULL
range	NULL
of	NULL
chloramphenicol	NULL
substrate	NULL
conversion	NULL
,	NULL
resulting	NULL
in	NULL
conversion	NULL
of	NULL
29.4	NULL
%	NULL
for	NULL
£300	NULL
WT	NULL
)	NULL
;	NULL
and	NULL
ENH	NULL
~	NULL
,	NULL
0.15	NULL
%	NULL
for	NULL
$	NULL
194	NULL
,	NULL
0.22	NULL
%	NULL
for	NULL
PD31	NULL
,	NULL
and	NULL
0.26	NULL
%	NULL
for	NULL
HAFTL	NULL
.	NULL

Activity	NULL
is	NULL
given	NULL
as	NULL
percent	NULL
relative	NULL
CAT	NULL
activity	NULL
of	NULL
the	NULL
wild-type	NULL
IgH	NULL
enhancer	NULL
fragment	NULL
.	NULL

Hatched	NULL
columns	NULL
represent	NULL
the	NULL
parental	NULL
enhancerless	NULL
plasmid	NULL
;	NULL
dotted	NULL
columns	NULL
represent	NULL
plasmids	NULL
containing	NULL
various	NULL
versions	NULL
of	NULL
the	NULL
enhancer	NULL
.	NULL

mutating	NULL
pB	NULL
in	NULL
this	NULL
fragment	NULL
,	NULL
the	NULL
simplest	NULL
explanation	NULL
is	NULL
that	NULL
pB	NULL
does	NULL
not	NULL
function	NULL
by	NULL
itself	NULL
but	NULL
requires	NULL
a	NULL
second	NULL
enhancer	NULL
element	NULL
such	NULL
as	NULL
E3	NULL
.	NULL

To	NULL
test	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
synthetic	NULL
34-bp	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
B	NULL
motif	NULL
and	NULL
its	NULL
flanking	NULL
region	NULL
but	NULL
lacking	NULL
E3	NULL
.	NULL

We	NULL
inserted	NULL
one	NULL
,	NULL
two	NULL
,	NULL
or	NULL
four	NULL
copies	NULL
of	NULL
this	NULL
oligonucleotide	NULL
into	NULL
the	NULL
AS6	NULL
plasmid	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
p70	NULL
fragment	NULL
,	NULL
no	NULL
enhancer	NULL
activity	NULL
,	NULL
even	NULL
with	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
mB	NULL
oligonucleotide	NULL
,	NULL
was	NULL
detected	NULL
in	NULL
$	NULL
194	NULL
,	NULL
PD31	NULL
,	NULL
or	NULL
HAFTL	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
the	NULL
mB	NULL
element	NULL
does	NULL
not	NULL
function	NULL
independently	NULL
as	NULL
an	NULL
enhancer	NULL
but	NULL
needs	NULL
interaction	NULL
with	NULL
another	NULL
enhancer	NULL
element	NULL
for	NULL
activity	NULL
.	NULL

pB	NULL
and	NULL
OCTA	NULL
are	NULL
not	NULL
functional	NULL
in	NULL
fibroblasts	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
pB	NULL
is	NULL
functional	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
,	NULL
we	NULL
trans-	NULL
fected	NULL
the	NULL
various	NULL
constructs	NULL
into	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
.	NULL

All	NULL
constructs	NULL
derived	NULL
from	NULL
the	NULL
700	NULL
enhancer	NULL
as	NULL
well	NULL
as	NULL
the	NULL
p70	NULL
constructs	NULL
were	NULL
inactive	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
.	NULL

w300	NULL
WT	NULL
expressed	NULL
low	NULL
but	NULL
reproducible	NULL
enhancer	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Mutation	NULL
of	NULL
the	NULL
OCTA	NULL
or	NULL
mB	NULL
site	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
both	NULL
within	NULL
1300	NULL
resulted	NULL
in	NULL
a	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

We	NULL
have	NULL
not	NULL
further	NULL
investigated	NULL
the	NULL
apparent	NULL
inhibitory	NULL
effects	NULL
of	NULL
these	NULL
motifs	NULL
in	NULL
fibroblasts	NULL
,	NULL
but	NULL
it	NULL
is	NULL
evident	NULL
that	NULL
the	NULL
activation	NULL
effects	NULL
of	NULL
the	NULL
motifs	NULL
are	NULL
manifest	NULL
specifically	NULL
in	NULL
B	NULL
cells	NULL
but	NULL
not	NULL
fibroblasts	NULL
.	NULL

A	NULL
lymphoid-specific	NULL
protein	NULL
binds	NULL
to	NULL
the	NULL
B	NULL
DNA	NULL
motif	NULL
.	NULL

To	NULL
correlate	NULL
the	NULL
functional	NULL
data	NULL
described	NULL
above	NULL
with	NULL
binding	NULL
of	NULL
a	NULL
potential	NULL
lymphoid-specific	NULL
protein	NULL
to	NULL
the	NULL
wB	NULL
motif	NULL
,	NULL
we	NULL
performed	NULL
DNase	NULL
I	NULL
footprinting	NULL
experiments	NULL
using	NULL
the	NULL
1460	NULL
Vor	NULL
.	NULL

10	NULL
,	NULL
1990	NULL
300|-	NULL
%	NULL
RELATIVE	NULL
CAT	NULL
ACTIVITY	NULL
WT	NULL
0~	NULL
B-	NULL
O	NULL
aB	NULL
ENH~	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Effects	NULL
of	NULL
mutation	NULL
in	NULL
the	NULL
B	NULL
motif	NULL
within	NULL
the	NULL
1300	NULL
IgH	NULL
enhancer	NULL
on	NULL
transcription	NULL
in	NULL
fibroblasts	NULL
.	NULL

The	NULL
£300	NULL
IgH	NULL
enhancers	NULL
were	NULL
tested	NULL
in	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
.	NULL

Absolute	NULL
percent	NULL
conversions	NULL
of	NULL
chloramphenicol	NULL
to	NULL
acetylated	NULL
forms	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
300	NULL
WT	NULL
,	NULL
1.1	NULL
%	NULL
and	NULL
ENH~	NULL
,	NULL
0.85	NULL
%	NULL
.	NULL

Other	NULL
details	NULL
are	NULL
as	NULL
given	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3.	NULL
fragment	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

We	NULL
compared	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
lymphoid	NULL
cells	NULL
with	NULL
extracts	NULL
from	NULL
nonlymphoid	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
and	NULL
6	NULL
)	NULL
.	NULL

Proteins	NULL
bound	NULL
to	NULL
E2	NULL
and	NULL
E3	NULL
were	NULL
detected	NULL
in	NULL
extracts	NULL
of	NULL
both	NULL
lymphoid	NULL
(	NULL
$	NULL
194	NULL
and	NULL
BJAB	NULL
)	NULL
and	NULL
nonlymphoid	NULL
(	NULL
U-C12:6	NULL
,	NULL
32D	NULL
,	NULL
NIH	NULL
3T3	NULL
,	NULL
EJ	NULL
,	NULL
and	NULL
HeLa	NULL
)	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
and	NULL
6A	NULL
)	NULL
.	NULL

A	NULL
strong	NULL
footprint	NULL
over	NULL
the	NULL
wB	NULL
DNA	NULL
motif	NULL
was	NULL
seen	NULL
in	NULL
extracts	NULL
from	NULL
the	NULL
two	NULL
lymphoid	NULL
cell	NULL
lines	NULL
$	NULL
194	NULL
(	NULL
murine	NULL
myeloma	NULL
)	NULL
and	NULL
BJAB	NULL
(	NULL
human	NULL
B-cell	NULL
lymphoma	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
;	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

No	NULL
footprint	NULL
over	NULL
the	NULL
pB	NULL
site	NULL
was	NULL
observed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
U-C12:6	NULL
,	NULL
a	NULL
human	NULL
glioma	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
NIH	NULL
3T3	NULL
mouse	NULL
fibroblasts	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
EJ	NULL
human	NULL
bladder	NULL
carcinoma	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
and	NULL
HeLa	NULL
human	NULL
cervical	NULL
carcinoma	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

The	NULL
nuclear	NULL
extract	NULL
from	NULL
the	NULL
32D	NULL
myeloid	NULL
precursor	NULL
cell	NULL
line	NULL
protected	NULL
a	NULL
larger	NULL
region	NULL
around	NULL
the	NULL
wB	NULL
site	NULL
and	NULL
had	NULL
a	NULL
unique	NULL
enhanced	NULL
band	NULL
in	NULL
the	NULL
upper	NULL
part	NULL
of	NULL
the	NULL
pB	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
32D	NULL
nuclear	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
has	NULL
properties	NULL
very	NULL
different	NULL
from	NULL
those	NULL
of	NULL
the	NULL
B-cell	NULL
factor	NULL
.	NULL

Our	NULL
results	NULL
confirm	NULL
that	NULL
a	NULL
lymphoid-specific	NULL
factor	NULL
or	NULL
factors	NULL
in	NULL
both	NULL
murine	NULL
and	NULL
human	NULL
cells	NULL
bind	NULL
to	NULL
the	NULL
B	NULL
motif	NULL
.	NULL

Interestingly	NULL
,	NULL
we	NULL
also	NULL
detected	NULL
a	NULL
strong	NULL
lymphoid-specific	NULL
footprint	NULL
between	NULL
the	NULL
E2-	NULL
and	NULL
E3-binding	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
which	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
observed	NULL
.	NULL

This	NULL
suggests	NULL
the	NULL
possibility	NULL
of	NULL
additional	NULL
lymphoid-specific	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
(	NULL
T.	NULL
Libermann	NULL
and	NULL
D.	NULL
Baltimore	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
mutation	NULL
in	NULL
wB	NULL
decreased	NULL
binding	NULL
of	NULL
the	NULL
lymphoid-specific	NULL
factor	NULL
,	NULL
we	NULL
carried	NULL
out	NULL
DNase	NULL
I	NULL
footprinting	NULL
experiments	NULL
comparing	NULL
the	NULL
wild-type	NULL
460	NULL
WT	NULL
with	NULL
the	NULL
mutant	NULL
460	NULL
wB~	NULL
enhancer	NULL
.	NULL

Heparin-agarose	NULL
fractions	NULL
of	NULL
nuclear	NULL
extracts	NULL
derived	NULL
from	NULL
HeLa	NULL
and	NULL
BJAB	NULL
cells	NULL
were	NULL
used	NULL
for	NULL
this	NULL
experiment	NULL
.	NULL

Again	NULL
,	NULL
only	NULL
the	NULL
BJAB	NULL
B-cell	NULL
line	NULL
,	NULL
not	NULL
the	NULL
HeLa	NULL
carcinoma	NULL
cell	NULL
line	NULL
,	NULL
extract	NULL
gave	NULL
rise	NULL
to	NULL
a	NULL
footprint	NULL
over	NULL
the	NULL
mB	NULL
site	NULL
in	NULL
the	NULL
wild-type	NULL
enhancer	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

The	NULL
mutant	NULL
uB	NULL
site	NULL
gave	NULL
a	NULL
different	NULL
DNase	NULL
digestion	NULL
pattern	NULL
,	NULL
but	NULL
it	NULL
was	NULL
clear	NULL
that	NULL
no	NULL
protection	NULL
was	NULL
detected	NULL
over	NULL
the	NULL
altered	NULL
pB	NULL
site	NULL
with	NULL
an	NULL
extract	NULL
from	NULL
BJAB	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

A	NULL
weak	NULL
footprint	NULL
that	NULL
included	NULL
the	NULL
mutant	NULL
pB	NULL
site	NULL
was	NULL
created	NULL
by	NULL
the	NULL
HeLa	NULL
extract	NULL
,	NULL
but	NULL
this	NULL
has	NULL
not	NULL
been	NULL
further	NULL
studied	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
have	NULL
been	NULL
confirmed	NULL
by	NULL
gel	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
Libermann	NULL
and	NULL
Baltimore	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Only	NULL
a	NULL
wild-type	NULL
,	NULL
not	NULL
a	NULL
mutant	NULL
B	NULL
,	NULL
oligonucleotide	NULL
forms	NULL
a	NULL
specific	NULL
complex	NULL
in	NULL
B	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
glioma	NULL
,	NULL
epithelial	NULL
,	NULL
and	NULL
fibroblast	NULL
cells	NULL
,	NULL
and	NULL
only	NULL
the	NULL
wild-type	NULL
oligo-	NULL
LYMPHOID-SPECIFIC	NULL
ENHANCER	NULL
ELEMENT	NULL
IN	NULL
IgH	NULL
GENE	NULL
3159	NULL
NIH	NULL
3T	NULL
3	NULL
No	NULL
Protein	NULL
G+A	NULL
W	NULL
O	NULL
BJAB	NULL
$	NULL
194	NULL
32D	NULL
ee	NULL
rA	NULL
CL	NULL
359	NULL
&	NULL
7	NULL
|	NULL
5	NULL
|	NULL
(	NULL
-	NULL
383	NULL
pay	NULL
w*	NULL
wit	NULL
wat	NULL
-	NULL
|	NULL
ses	NULL
&	NULL
ry	NULL
401	NULL
C3	NULL
#	NULL
m	NULL
wag	NULL
a**	NULL
crn	NULL
a	NULL
C	NULL
—r	NULL
‘	NULL
—408	NULL
#	NULL
s	NULL
=	NULL
AL-414	NULL
€	NULL
is	NULL
-	NULL
as	NULL
is	NULL
LB	NULL
4-42	NULL
C1	NULL
FR	NULL
mm	NULL
z	NULL
-440	NULL
|	NULL
|	NULL
i-	NULL
454	NULL
a	NULL
?	NULL

!	NULL

®	NULL
+	NULL
2p	NULL
y	NULL
45	NULL
6	NULL
7	NULL
8	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Detection	NULL
of	NULL
IgH	NULL
enhancer-binding	NULL
factors	NULL
by	NULL
a	NULL
DNase	NULL
I	NULL
footprinting	NULL
assay	NULL
using	NULL
wild-type	NULL
460	NULL
IgH	NULL
enhancer	NULL
fragment	NULL
labeled	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
noncoding	NULL
strand	NULL
.	NULL

Labeled	NULL
460	NULL
enhancer	NULL
fragment	NULL
was	NULL
incubated	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
total	NULL
nuclear	NULL
extract	NULL
from	NULL
U-C12:6	NULL
glioma	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
32D	NULL
myeloid	NULL
precursor	NULL
cells	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
NIH	NULL
3T3	NULL
fibroblasts	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
EJ	NULL
bladder	NULL
carcinoma	NULL
cells	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
BJAB	NULL
B-lymphoid	NULL
cells	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
and	NULL
$	NULL
194	NULL
myeloma	NULL
cells	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Lane	NULL
7	NULL
was	NULL
a	NULL
control	NULL
reaction	NULL
without	NULL
protein	NULL
.	NULL

A	NULL
G+A	NULL
Maxam-Gilbert	NULL
sequence	NULL
reaction	NULL
of	NULL
the	NULL
same	NULL
IgH	NULL
enhancer	NULL
fragment	NULL
was	NULL
run	NULL
in	NULL
lane	NULL
8	NULL
.	NULL

The	NULL
positions	NULL
and	NULL
names	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
elements	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
boxes	NULL
to	NULL
the	NULL
right	NULL
of	NULL
gel	NULL
,	NULL
together	NULL
with	NULL
coordinates	NULL
of	NULL
each	NULL
site	NULL
according	NULL
to	NULL
Ephrussi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
8	NULL
)	NULL
.	NULL

nucleotide	NULL
specifically	NULL
competes	NULL
with	NULL
this	NULL
particular	NULL
complex	NULL
(	NULL
Libermann	NULL
and	NULL
Baltimore	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
mutation	NULL
in	NULL
the	NULL
pB	NULL
site	NULL
indeed	NULL
decreases	NULL
affinity	NULL
for	NULL
a	NULL
lymphoid-specific	NULL
wB-binding	NULL
factor	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
found	NULL
that	NULL
the	NULL
mB	NULL
site	NULL
found	NULL
just	NULL
downstream	NULL
of	NULL
the	NULL
E3	NULL
site	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
is	NULL
a	NULL
crucial	NULL
component	NULL
of	NULL
the	NULL
3160	NULL
LIBERMANN	NULL
ET	NULL
AL	NULL
.	NULL

!	NULL

+	NULL
.Q6M+M	NULL
``	NULL
if	NULL
``	NULL
#	NULL
#	NULL
``	NULL
P	NULL
+	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
factors	NULL
to	NULL
wild-type	NULL
and	NULL
mutant	NULL
mB	NULL
sites	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
in	NULL
a	NULL
DNase	NULL
I	NULL
footprinting	NULL
assay	NULL
using	NULL
wild-type	NULL
460	NULL
WT	NULL
(	NULL
A	NULL
)	NULL
and	NULL
mutant	NULL
p460	NULL
B-	NULL
(	NULL
B	NULL
)	NULL
IgH	NULL
enhancer	NULL
fragments	NULL
labeled	NULL
and	NULL
cut	NULL
as	NULL
for	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Labeled	NULL
enhancer	NULL
fragments	NULL
were	NULL
incubated	NULL
with	NULL
3	NULL
pg	NULL
of	NULL
heparin-agarose-purified	NULL
nuclear	NULL
extract	NULL
from	NULL
HeLa	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
BJAB	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
cells	NULL
.	NULL

Lane	NULL
1	NULL
was	NULL
a	NULL
control	NULL
reaction	NULL
without	NULL
protein	NULL
.	NULL

A	NULL
G+A	NULL
sequence	NULL
reaction	NULL
of	NULL
the	NULL
same	NULL
DNA	NULL
fragments	NULL
was	NULL
run	NULL
as	NULL
a	NULL
marker	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

The	NULL
positions	NULL
and	NULL
names	NULL
of	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
are	NULL
indicated	NULL
by	NULL
solid	NULL
boxes	NULL
together	NULL
with	NULL
coordinates	NULL
(	NULL
8	NULL
,	NULL
16	NULL
)	NULL
of	NULL
each	NULL
site	NULL
.	NULL

The	NULL
box	NULL
with	NULL
dashed	NULL
lines	NULL
in	NULL
panel	NULL
B	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
the	NULL
altered	NULL
mB	NULL
site	NULL
.	NULL

IgH	NULL
gene	NULL
regulatory	NULL
region	NULL
.	NULL

The	NULL
mB	NULL
motif	NULL
binds	NULL
a	NULL
lymphoid-specific	NULL
nuclear	NULL
factor	NULL
,	NULL
and	NULL
its	NULL
alteration	NULL
substantially	NULL
reduces	NULL
IgH	NULL
enhancer	NULL
activity	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
combined	NULL
mutation	NULL
of	NULL
both	NULL
wB	NULL
and	NULL
OCTA	NULL
sites	NULL
drastically	NULL
impairs	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

Similar	NULL
results	NULL
have	NULL
been	NULL
obtained	NULL
independently	NULL
by	NULL
Nelsen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
to	NULL
induce	NULL
transcription	NULL
in	NULL
lymphoid	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
is	NULL
for	NULL
the	NULL
most	NULL
part	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
combined	NULL
action	NULL
of	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

two	NULL
enhancer	NULL
elements	NULL
,	NULL
B	NULL
and	NULL
OCTA	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
OCTA	NULL
(	NULL
45	NULL
)	NULL
,	NULL
however	NULL
,	NULL
the	NULL
wB	NULL
element	NULL
by	NULL
itself	NULL
does	NULL
not	NULL
express	NULL
enhancer	NULL
activity	NULL
but	NULL
needs	NULL
interaction	NULL
with	NULL
another	NULL
element	NULL
to	NULL
function	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
mB	NULL
site	NULL
,	NULL
together	NULL
with	NULL
the	NULL
OCTA	NULL
site	NULL
and	NULL
probably	NULL
others	NULL
,	NULL
determines	NULL
the	NULL
tissue-restricted	NULL
expression	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
.	NULL

Our	NULL
purpose	NULL
in	NULL
undertaking	NULL
these	NULL
studies	NULL
was	NULL
to	NULL
define	NULL
more	NULL
completely	NULL
which	NULL
enhancer	NULL
elements	NULL
contribute	NULL
to	NULL
the	NULL
lymphoid-restricted	NULL
expression	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
.	NULL

The	NULL
pB	NULL
motif	NULL
manifests	NULL
features	NULL
of	NULL
a	NULL
second	NULL
lymphoid-specific	NULL
element	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

Nevertheless	NULL
,	NULL
combined	NULL
mutation	NULL
of	NULL
both	NULL
the	NULL
B	NULL
and	NULL
OCTA	NULL
sites	NULL
leaves	NULL
considerable	NULL
residual	NULL
enhancer	NULL
activity	NULL
that	NULL
can	NULL
only	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
action	NULL
of	NULL
further	NULL
enhancer	NULL
elements	NULL
,	NULL
possibly	NULL
the	NULL
E	NULL
boxes	NULL
(	NULL
6	NULL
,	NULL
8	NULL
,	NULL
16	NULL
,	NULL
34	NULL
,	NULL
43	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
preliminary	NULL
evidence	NULL
suggests	NULL
that	NULL
an	NULL
mRNA	NULL
coding	NULL
for	NULL
an	NULL
E-box-binding	NULL
protein	NULL
is	NULL
preferentially	NULL
expressed	NULL
in	NULL
B	NULL
cells	NULL
(	NULL
C.	NULL
Murre	NULL
and	NULL
D.	NULL
Baltimore	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

B-cell	NULL
specificity	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
is	NULL
apparently	NULL
regulated	NULL
by	NULL
both	NULL
positive-acting	NULL
B-cell-specific	NULL
enhancer	NULL
elements	NULL
and	NULL
negative-acting	NULL
non-B-lymphoid-specific	NULL
elements	NULL
.	NULL

Indeed	NULL
,	NULL
recent	NULL
evidence	NULL
suggests	NULL
that	NULL
repression	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
silencing	NULL
of	NULL
the	NULL
enhancer	NULL
in	NULL
non-B	NULL
cells	NULL
(	NULL
30	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Two	NULL
negative	NULL
elements	NULL
that	NULL
flank	NULL
the	NULL
700-bp	NULL
IgH	NULL
enhancer	NULL
have	NULL
been	NULL
identified	NULL
and	NULL
might	NULL
be	NULL
related	NULL
to	NULL
matrix	NULL
attachment	NULL
points	NULL
(	NULL
30	NULL
)	NULL
.	NULL

It	NULL
is	NULL
therefore	NULL
not	NULL
surprising	NULL
that	NULL
a	NULL
300-bp	NULL
fragment	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
(	NULL
300	NULL
)	NULL
is	NULL
somewhat	NULL
transcriptionally	NULL
active	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
whole	NULL
700	NULL
IgH	NULL
enhancer	NULL
is	NULL
inactive	NULL
in	NULL
nonlymphoid	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

An	NULL
apparent	NULL
negative	NULL
element	NULL
has	NULL
been	NULL
located	NULL
to	NULL
a	NULL
region	NULL
between	NULL
the	NULL
E1	NULL
and	NULL
E2	NULL
enhancer	NULL
elements	NULL
(	NULL
44	NULL
)	NULL
.	NULL

This	NULL
negative	NULL
element	NULL
suppresses	NULL
enhancer	NULL
activity	NULL
in	NULL
non-B	NULL
cells	NULL
and	NULL
is	NULL
absent	NULL
in	NULL
the	NULL
300	NULL
fragment	NULL
(	NULL
44	NULL
)	NULL
.	NULL

However	NULL
,	NULL
even	NULL
the	NULL
300-bp	NULL
fragment	NULL
which	NULL
lacks	NULL
identified	NULL
negative	NULL
elements	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
very	NULL
weak	NULL
enhancer	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
if	NULL
compared	NULL
with	NULL
B	NULL
cells	NULL
.	NULL

Mutation	NULL
of	NULL
either	NULL
the	NULL
OCTA	NULL
or	NULL
wB	NULL
site	NULL
leads	NULL
to	NULL
increased	NULL
activity	NULL
of	NULL
300	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
factors	NULL
binding	NULL
to	NULL
these	NULL
sites	NULL
in	NULL
NIH	NULL
3T3	NULL
cells	NULL
might	NULL
repress	NULL
rather	NULL
than	NULL
enhance	NULL
activity	NULL
.	NULL

Another	NULL
less	NULL
likely	NULL
explanation	NULL
might	NULL
be	NULL
that	NULL
mutation	NULL
of	NULL
these	NULL
sites	NULL
allows	NULL
binding	NULL
of	NULL
positive	NULL
factors	NULL
to	NULL
the	NULL
mutated	NULL
sites	NULL
that	NULL
are	NULL
specific	NULL
for	NULL
NIH	NULL
3T3	NULL
cells	NULL
.	NULL

Negative	NULL
regulation	NULL
may	NULL
contribute	NULL
to	NULL
lymphoid	NULL
specificity	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

However	NULL
,	NULL
positive-acting	NULL
lymphoid-specific	NULL
elements	NULL
are	NULL
essential	NULL
to	NULL
explain	NULL
all	NULL
aspects	NULL
of	NULL
lymphoid-specific	NULL
IgH	NULL
enhancer	NULL
expression	NULL
.	NULL

Mutation	NULL
in	NULL
the	NULL
OCTA	NULL
site	NULL
within	NULL
300	NULL
did	NULL
not	NULL
lead	NULL
to	NULL
as	NULL
drastic	NULL
a	NULL
decrease	NULL
in	NULL
transcriptional	NULL
activity	NULL
as	NULL
previously	NULL
reported	NULL
(	NULL
16	NULL
)	NULL
but	NULL
reduced	NULL
CAT	NULL
activity	NULL
by	NULL
only	NULL
50	NULL
to	NULL
60	NULL
%	NULL
in	NULL
different	NULL
B-cell	NULL
lines	NULL
.	NULL

This	NULL
discrepancy	NULL
might	NULL
be	NULL
due	NULL
to	NULL
the	NULL
use	NULL
of	NULL
different	NULL
cell	NULL
lines	NULL
in	NULL
the	NULL
previous	NULL
report	NULL
.	NULL

More	NULL
important	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
pB	NULL
site	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
revealed	NULL
a	NULL
greater	NULL
decrease	NULL
in	NULL
transcription	NULL
than	NULL
did	NULL
mutation	NULL
in	NULL
the	NULL
OCTA	NULL
site	NULL
.	NULL

This	NULL
difference	NULL
was	NULL
independent	NULL
of	NULL
the	NULL
length	NULL
of	NULL
IgH	NULL
enhancer	NULL
fragment	NULL
tested	NULL
.	NULL

This	NULL
difference	NULL
was	NULL
particularly	NULL
striking	NULL
in	NULL
the	NULL
pre-B-cell	NULL
line	NULL
PD31	NULL
and	NULL
might	NULL
be	NULL
due	NULL
to	NULL
different	NULL
amounts	NULL
of	NULL
NF-pB	NULL
and	NULL
Oct-2	NULL
protein	NULL
in	NULL
PD31	NULL
pre-B	NULL
cells	NULL
and	NULL
$	NULL
194	NULL
myeloma	NULL
cells	NULL
.	NULL

PD31	NULL
cells	NULL
might	NULL
contain	NULL
relatively	NULL
more	NULL
NF-pB	NULL
than	NULL
$	NULL
194	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
the	NULL
B	NULL
orientation	NULL
L300	NULL
expressed	NULL
much	NULL
higher	NULL
transcriptional	NULL
activity	NULL
than	NULL
did	NULL
700	NULL
,	NULL
whereas	NULL
in	NULL
the	NULL
A	NULL
orientation	NULL
L700	NULL
was	NULL
more	NULL
active	NULL
than	NULL
300	NULL
.	NULL

This	NULL
effect	NULL
might	NULL
be	NULL
due	NULL
to	NULL
the	NULL
difference	NULL
in	NULL
activity	NULL
of	NULL
the	NULL
various	NULL
enhancer	NULL
elements	NULL
dependent	NULL
on	NULL
the	NULL
distance	NULL
to	NULL
the	NULL
c-fos	NULL
promoter	NULL
.	NULL

In	NULL
the	NULL
B	NULL
orientation	NULL
but	NULL
not	NULL
in	NULL
the	NULL
A	NULL
orientation	NULL
,	NULL
E3	NULL
,	NULL
pB	NULL
,	NULL
and	NULL
OCTA	NULL
Vor	NULL
.	NULL

10	NULL
,	NULL
1990	NULL
are	NULL
closer	NULL
to	NULL
the	NULL
transcription	NULL
initiation	NULL
point	NULL
in	NULL
300	NULL
than	NULL
in	NULL
L700	NULL
.	NULL

Using	NULL
the	NULL
DNase	NULL
I	NULL
footprinting	NULL
technique	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
specific	NULL
binding	NULL
of	NULL
a	NULL
nuclear	NULL
factor	NULL
or	NULL
factors	NULL
,	NULL
termed	NULL
NF-pB	NULL
,	NULL
to	NULL
the	NULL
B	NULL
site	NULL
of	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
.	NULL

NF-uB	NULL
seems	NULL
to	NULL
be	NULL
present	NULL
only	NULL
in	NULL
B-lymphoid	NULL
and	NULL
some	NULL
T-lymphoid	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
macro-phage	NULL
cell	NULL
lines	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
of	NULL
both	NULL
human	NULL
and	NULL
mouse	NULL
origin	NULL
but	NULL
is	NULL
absent	NULL
in	NULL
fibroblasts	NULL
,	NULL
epithelial	NULL
cells	NULL
,	NULL
and	NULL
glial	NULL
cells	NULL
.	NULL

Partial	NULL
protection	NULL
of	NULL
the	NULL
wB	NULL
site	NULL
was	NULL
also	NULL
detected	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
myeloid	NULL
precursor	NULL
cell	NULL
line	NULL
32D	NULL
,	NULL
even	NULL
though	NULL
the	NULL
footprint	NULL
pattern	NULL
over	NULL
the	NULL
mB	NULL
site	NULL
was	NULL
strikingly	NULL
different	NULL
from	NULL
that	NULL
created	NULL
by	NULL
nuclear	NULL
extracts	NULL
from	NULL
lymphoid	NULL
cells	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
factor	NULL
related	NULL
but	NULL
not	NULL
identical	NULL
to	NULL
NF-uB	NULL
.	NULL

Both	NULL
DNase	NULL
I	NULL
footprinting	NULL
analysis	NULL
and	NULL
gel	NULL
mobility	NULL
shift	NULL
experiments	NULL
(	NULL
unpublished	NULL
results	NULL
)	NULL
have	NULL
confirmed	NULL
that	NULL
the	NULL
mutant	NULL
mB	NULL
site	NULL
is	NULL
unable	NULL
to	NULL
bind	NULL
NF-uB	NULL
.	NULL

Unexpectedly	NULL
,	NULL
we	NULL
observed	NULL
an	NULL
additional	NULL
putative	NULL
lymphoid-specific	NULL
footprint	NULL
in	NULL
the	NULL
region	NULL
between	NULL
the	NULL
ubiquitously	NULL
protected	NULL
E2	NULL
and	NULL
E3	NULL
sites	NULL
,	NULL
raising	NULL
the	NULL
possibility	NULL
that	NULL
a	NULL
third	NULL
lymphoid-specific	NULL
enhancer	NULL
element	NULL
is	NULL
present	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

We	NULL
have	NULL
preliminary	NULL
evidence	NULL
that	NULL
this	NULL
new	NULL
site	NULL
is	NULL
indeed	NULL
a	NULL
functional	NULL
enhancer	NULL
(	NULL
Libermann	NULL
and	NULL
Baltimore	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Lymphoid-specific	NULL
protection	NULL
over	NULL
the	NULL
mB	NULL
site	NULL
has	NULL
been	NULL
previously	NULL
suggested	NULL
by	NULL
the	NULL
experiments	NULL
of	NULL
Ephrussi	NULL
et	NULL
al	NULL
.	NULL

(	NULL
8	NULL
)	NULL
with	NULL
in	NULL
vivo	NULL
experiments	NULL
and	NULL
by	NULL
Augereau	NULL
and	NULL
Chambon	NULL
(	NULL
2	NULL
)	NULL
with	NULL
in	NULL
vitro	NULL
DNase	NULL
footprinting	NULL
.	NULL

Araki	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
have	NULL
recently	NULL
reported	NULL
the	NULL
purification	NULL
of	NULL
a	NULL
nuclear	NULL
protein	NULL
from	NULL
a	NULL
murine	NULL
myeloma	NULL
that	NULL
binds	NULL
to	NULL
a	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IgH	NULL
enhancer	NULL
that	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
wB	NULL
site	NULL
,	NULL
although	NULL
the	NULL
murine	NULL
mB	NULL
sequence	NULL
differs	NULL
in	NULL
4	NULL
of	NULL
16	NULL
nucleotides	NULL
from	NULL
the	NULL
human	NULL
pB-like	NULL
site	NULL
.	NULL

We	NULL
now	NULL
demonstrate	NULL
that	NULL
the	NULL
murine	NULL
pB	NULL
site	NULL
has	NULL
features	NULL
resembling	NULL
the	NULL
human	NULL
homolog	NULL
(	NULL
see	NULL
also	NULL
Nelsen	NULL
et	NULL
al	NULL
.	NULL

[	NULL
24	NULL
]	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
like	NULL
the	NULL
OCTA	NULL
motif	NULL
,	NULL
the	NULL
B	NULL
motif	NULL
and	NULL
its	NULL
factor	NULL
are	NULL
important	NULL
elements	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
that	NULL
are	NULL
apparently	NULL
conserved	NULL
between	NULL
species	NULL
.	NULL

Araki	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
showed	NULL
that	NULL
their	NULL
factor	NULL
is	NULL
capable	NULL
of	NULL
inducing	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
IgH	NULL
gene	NULL
when	NULL
introduced	NULL
into	NULL
mouse	NULL
L	NULL
cells	NULL
containing	NULL
a	NULL
transfected	NULL
rearranged	NULL
IgH	NULL
gene	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
nonlymphoid	NULL
cell	NULL
lines	NULL
were	NULL
unable	NULL
to	NULL
induce	NULL
high	NULL
expression	NULL
of	NULL
the	NULL
IgH	NULL
gene	NULL
in	NULL
L	NULL
cells	NULL
.	NULL

Our	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
mB	NULL
motif	NULL
in	NULL
the	NULL
murine	NULL
IgH	NULL
enhancer	NULL
provides	NULL
evidence	NULL
that	NULL
the	NULL
murine	NULL
pB	NULL
site	NULL
has	NULL
features	NULL
similar	NULL
to	NULL
the	NULL
human	NULL
homolog	NULL
.	NULL

Our	NULL
results	NULL
show	NULL
directly	NULL
that	NULL
the	NULL
mB	NULL
motif	NULL
plays	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
IgH	NULL
enhancer	NULL
activity	NULL
and	NULL
together	NULL
with	NULL
the	NULL
DNase	NULL
footprinting	NULL
experiments	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
the	NULL
wB	NULL
motif	NULL
acts	NULL
as	NULL
a	NULL
lymphoid-specific	NULL
enhancer	NULL
component	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
wB	NULL
motif	NULL
appears	NULL
to	NULL
have	NULL
a	NULL
stronger	NULL
effect	NULL
on	NULL
IgH	NULL
enhancer	NULL
transcription	NULL
in	NULL
pre-B	NULL
cells	NULL
than	NULL
does	NULL
the	NULL
OCTA	NULL
element	NULL
.	NULL

There	NULL
is	NULL
an	NULL
important	NULL
difference	NULL
between	NULL
the	NULL
function	NULL
of	NULL
the	NULL
OCTA	NULL
and	NULL
the	NULL
B	NULL
elements	NULL
.	NULL

The	NULL
OCTA	NULL
motif	NULL
acts	NULL
as	NULL
a	NULL
lymphoid-specific	NULL
enhancer	NULL
independently	NULL
of	NULL
other	NULL
enhancer	NULL
elements	NULL
(	NULL
45	NULL
)	NULL
,	NULL
whereas	NULL
even	NULL
a	NULL
tetramer	NULL
of	NULL
the	NULL
mB	NULL
motif	NULL
is	NULL
completely	NULL
devoid	NULL
of	NULL
enhancer	NULL
activity	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
lines	NULL
tested	NULL
.	NULL

Nevertheless	NULL
,	NULL
transcription	NULL
of	NULL
a	NULL
small	NULL
70-bp	NULL
fragment	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
that	NULL
contains	NULL
the	NULL
E3	NULL
and	NULL
mB	NULL
sites	NULL
works	NULL
as	NULL
an	NULL
enhancer	NULL
element	NULL
and	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
integrity	NULL
of	NULL
the	NULL
mB	NULL
site	NULL
.	NULL

There	NULL
are	NULL
several	NULL
explanations	NULL
for	NULL
the	NULL
lack	NULL
of	NULL
independent	NULL
enhancer	NULL
activity	NULL
of	NULL
the	NULL
mB	NULL
element	NULL
.	NULL

(	NULL
i	NULL
)	NULL
We	NULL
might	NULL
have	NULL
missed	NULL
part	NULL
of	NULL
the	NULL
NF-uB-binding	NULL
site	NULL
when	NULL
constructing	NULL
the	NULL
oligonucleotide	NULL
.	NULL

This	NULL
is	NULL
unlikely	NULL
,	NULL
because	NULL
our	NULL
oligonucleotide	NULL
contains	NULL
flanking	NULL
regions	NULL
on	NULL
LYMPHOID-SPECIFIC	NULL
ENHANCER	NULL
ELEMENT	NULL
IN	NULL
IgH	NULL
GENE	NULL
3161	NULL
both	NULL
ends	NULL
extending	NULL
well	NULL
over	NULL
the	NULL
putative	NULL
binding	NULL
site	NULL
described	NULL
by	NULL
Araki	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
for	NULL
the	NULL
human	NULL
wB-like	NULL
element	NULL
and	NULL
functionally	NULL
defined	NULL
by	NULL
Nelsen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
.	NULL

(	NULL
ii	NULL
)	NULL
The	NULL
pB	NULL
motif	NULL
is	NULL
inactive	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
c-fos	NULL
promoter/CAT	NULL
construct	NULL
.	NULL

This	NULL
is	NULL
also	NULL
unlikely	NULL
,	NULL
because	NULL
the	NULL
wB	NULL
element	NULL
acts	NULL
as	NULL
an	NULL
enhancer	NULL
in	NULL
this	NULL
plasmid	NULL
in	NULL
the	NULL
context	NULL
of	NULL
other	NULL
IgH	NULL
enhancer	NULL
elements	NULL
.	NULL

(	NULL
iii	NULL
)	NULL
The	NULL
spacing	NULL
of	NULL
the	NULL
B	NULL
motifs	NULL
in	NULL
the	NULL
multimers	NULL
does	NULL
not	NULL
allow	NULL
``	NULL
productive	NULL
``	NULL
NF-puB	NULL
binding	NULL
to	NULL
the	NULL
element	NULL
.	NULL

At	NULL
present	NULL
we	NULL
have	NULL
no	NULL
evidence	NULL
against	NULL
or	NULL
for	NULL
this	NULL
possibility	NULL
.	NULL

(	NULL
iv	NULL
)	NULL
Interactions	NULL
between	NULL
NF-puB	NULL
and	NULL
proteins	NULL
binding	NULL
to	NULL
additional	NULL
enhancer	NULL
elements	NULL
are	NULL
needed	NULL
for	NULL
the	NULL
function	NULL
of	NULL
the	NULL
wB	NULL
element	NULL
,	NULL
or	NULL
NF-uB	NULL
binds	NULL
only	NULL
after	NULL
modulation	NULL
of	NULL
the	NULL
B	NULL
site	NULL
by	NULL
an	NULL
additional	NULL
enhancer	NULL
element	NULL
.	NULL

Our	NULL
results	NULL
support	NULL
this	NULL
explanation	NULL
,	NULL
because	NULL
alteration	NULL
of	NULL
either	NULL
the	NULL
pB	NULL
or	NULL
the	NULL
E3	NULL
site	NULL
within	NULL
the	NULL
70	NULL
IgH	NULL
enhancer	NULL
fragment	NULL
abolished	NULL
most	NULL
if	NULL
not	NULL
all	NULL
enhancer	NULL
activity	NULL
of	NULL
this	NULL
fragment	NULL
.	NULL

Whether	NULL
E3	NULL
is	NULL
the	NULL
only	NULL
enhancer	NULL
element	NULL
that	NULL
directly	NULL
interacts	NULL
with	NULL
B	NULL
we	NULL
do	NULL
not	NULL
yet	NULL
know	NULL
.	NULL

Also	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
whether	NULL
NF-pB	NULL
and	NULL
NF-uE3	NULL
can	NULL
directly	NULL
interact	NULL
.	NULL

Interestingly	NULL
,	NULL
Meyer	NULL
and	NULL
Neuberger	NULL
(	NULL
22	NULL
)	NULL
have	NULL
recently	NULL
identified	NULL
an	NULL
enhancer	NULL
3	NULL
'	NULL
of	NULL
the	NULL
immunoglobulin	NULL
k	NULL
gene	NULL
that	NULL
contains	NULL
a	NULL
pB-like	NULL
sequence	NULL
flanked	NULL
by	NULL
an	NULL
E3-like	NULL
motif	NULL
,	NULL
albeit	NULL
in	NULL
orientation	NULL
inverse	NULL
to	NULL
that	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
.	NULL

The	NULL
novel	NULL
immunoglobulin	NULL
xk	NULL
enhancer	NULL
they	NULL
describe	NULL
also	NULL
contains	NULL
a	NULL
sequence	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
new	NULL
enhancer	NULL
element	NULL
found	NULL
between	NULL
E2	NULL
and	NULL
E3	NULL
in	NULL
the	NULL
IgH	NULL
enhancer	NULL
(	NULL
Libermann	NULL
and	NULL
Baltimore	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Interactions	NULL
between	NULL
different	NULL
enhancer	NULL
elements	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
important	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
lack	NULL
of	NULL
demonstrable	NULL
activity	NULL
of	NULL
wB	NULL
oligonu-cleotides	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
other	NULL
enhancer	NULL
elements	NULL
and	NULL
their	NULL
associated	NULL
binding	NULL
proteins	NULL
modulate	NULL
the	NULL
transcriptional	NULL
effect	NULL
of	NULL
the	NULL
mB	NULL
motif	NULL
will	NULL
be	NULL
an	NULL
interesting	NULL
area	NULL
for	NULL
future	NULL
research	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Barbara	NULL
Nelsen	NULL
,	NULL
Tom	NULL
Kadesch	NULL
,	NULL
and	NULL
Ranjan	NULL
Sen	NULL
for	NULL
communicating	NULL
their	NULL
results	NULL
to	NULL
us	NULL
prior	NULL
to	NULL
publication	NULL
.	NULL

We	NULL
thank	NULL
Jacqueline	NULL
Pierce	NULL
and	NULL
Stephen	NULL
Smale	NULL
for	NULL
helpful	NULL
discussions	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
to	NULL
T.A.L	NULL
.	NULL

,	NULL
a	NULL
National	NULL
Cancer	NULL
Institute	NULL
clinical	NULL
investigator	NULL
award	NULL
to	NULL
M.L	NULL
.	NULL

,	NULL
and	NULL
Public	NULL
Health	NULL
Service	NULL
grant	NULL
GM	NULL
39458	NULL
to	NULL
D.B	NULL
.	NULL

from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Araki	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Maeda	NULL
,	NULL
J.	NULL
Wang	NULL
,	NULL
D.	NULL
Kitamura	NULL
,	NULL
and	NULL
T.	NULL
Watanabe	NULL
.	NULL

1988	NULL
.	NULL

Purification	NULL
of	NULL
a	NULL
nuclear	NULL
trans-acting	NULL
factor	NULL
involved	NULL
in	NULL
the	NULL
regulated	NULL
transcription	NULL
of	NULL
a	NULL
human	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
gene	NULL
.	NULL

Cell	NULL
53:723-730	NULL
.	NULL

2	NULL
.	NULL

Augereau	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
P.	NULL
Chambon	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
mouse	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
:	NULL
effect	NULL
on	NULL
transcription	NULL
in	NULL
vitro	NULL
and	NULL
binding	NULL
of	NULL
proteins	NULL
present	NULL
in	NULL
HeLa	NULL
and	NULL
lymphoid	NULL
B	NULL
cell	NULL
extract	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:1791-1797	NULL
.	NULL

3	NULL
.	NULL

Bergman	NULL
,	NULL
Y.	NULL
,	NULL
D.	NULL
Rice	NULL
,	NULL
R.	NULL
Grosschedl	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1984	NULL
.	NULL

Two	NULL
regulatory	NULL
elements	NULL
for	NULL
immunoglobulin	NULL
x	NULL
light	NULL
chain	NULL
gene	NULL
expression	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:7041-7045	NULL
.	NULL

4	NULL
.	NULL

Bohmann	NULL
,	NULL
D.	NULL
,	NULL
W.	NULL
Keller	NULL
,	NULL
T.	NULL
Dale	NULL
,	NULL
H.	NULL
R.	NULL
Schoeler	NULL
,	NULL
G.	NULL
Tebb	NULL
,	NULL
and	NULL
I.	NULL
W.	NULL
Mattaj	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
transcription	NULL
factor	NULL
which	NULL
binds	NULL
to	NULL
the	NULL
enhancers	NULL
of	NULL
SV40	NULL
,	NULL
immunoglobulin	NULL
heavy-chain	NULL
and	NULL
U2	NULL
snRNA	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
325:268-272	NULL
.	NULL

5	NULL
.	NULL

Carbon	NULL
,	NULL
P.	NULL
,	NULL
S.	NULL
Murgo	NULL
,	NULL
J.	NULL
P.	NULL
Ebel	NULL
,	NULL
A.	NULL
Krol	NULL
,	NULL
G.	NULL
Tebb	NULL
,	NULL
and	NULL
I.	NULL
Mattaj	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
common	NULL
octamer	NULL
motif	NULL
binding	NULL
protein	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
U6	NULL
snRNA	NULL
by	NULL
RNA	NULL
polymerase	NULL
III	NULL
and	NULL
U2	NULL
snRNA	NULL
polymerase	NULL
II	NULL
.	NULL

Cell	NULL
51:71-79	NULL
.	NULL

6	NULL
.	NULL

Church	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
A.	NULL
Ephrussi	NULL
,	NULL
W.	NULL
Gilbert	NULL
,	NULL
and	NULL
S.	NULL
Tonegawa	NULL
.	NULL

1985	NULL
.	NULL

Cell	NULL
type	NULL
specific	NULL
contacts	NULL
to	NULL
immunoglobulin	NULL
enhancers	NULL
in	NULL
nuclei	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
313:798-801	NULL
.	NULL

7	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
3162	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15.	NULL
o	NULL
17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

LIBERMANN	NULL
ET	NULL
AL	NULL
.	NULL

soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489.	NULL
.	NULL

Ephrussi	NULL
,	NULL
A.	NULL
,	NULL
G.	NULL
M.	NULL
Church	NULL
,	NULL
S.	NULL
Tonegawa	NULL
,	NULL
and	NULL
W.	NULL
Gilbert	NULL
.	NULL

1985	NULL
.	NULL

B	NULL
lineage-specific	NULL
interactions	NULL
of	NULL
an	NULL
immunoglobulin	NULL
enhancer	NULL
with	NULL
cellular	NULL
factors	NULL
in	NULL
vivo	NULL
.	NULL

Science	NULL
227:134-138.	NULL
.	NULL

Falkner	NULL
,	NULL
F.	NULL
G.	NULL
,	NULL
R.	NULL
Mocikat	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Zachau	NULL
.	NULL

1986	NULL
.	NULL

Sequences	NULL
closely	NULL
related	NULL
to	NULL
an	NULL
immunoglobulin	NULL
gene	NULL
promoter/enhancer	NULL
element	NULL
occur	NULL
also	NULL
upstream	NULL
of	NULL
other	NULL
eukaryotic	NULL
and	NULL
of	NULL
prokary-otic	NULL
genes	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14:8819-8827	NULL
.	NULL

Gilman	NULL
,	NULL
M.	NULL
Z.	NULL
,	NULL
R.	NULL
N.	NULL
Wilson	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Weinberg	NULL
.	NULL

1986	NULL
.	NULL

Multiple	NULL
protein-binding	NULL
sites	NULL
in	NULL
the	NULL
5'-flanking	NULL
region	NULL
regulate	NULL
c-fos	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:4305-4316	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
,	NULL
and	NULL
R.	NULL
Tijan	NULL
.	NULL

1985	NULL
.	NULL

Two	NULL
distinct	NULL
transcription	NULL
factors	NULL
bind	NULL
to	NULL
the	NULL
HSV	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
in	NULL
vitro	NULL
.	NULL

Cell	NULL
42:559-572	NULL
.	NULL

Kiledjian	NULL
,	NULL
M.	NULL
,	NULL
L.-K.	NULL
Su	NULL
,	NULL
and	NULL
T.	NULL
Kadesch	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
two	NULL
functional	NULL
domains	NULL
within	NULL
the	NULL
murine	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:145-152	NULL
.	NULL

Ko	NULL
,	NULL
H.-S.	NULL
,	NULL
P.	NULL
Fost	NULL
,	NULL
W.	NULL
McBride	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Staudt	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
human	NULL
protein	NULL
specific	NULL
for	NULL
immunoglobulin	NULL
octamer	NULL
DNA	NULL
motif	NULL
contains	NULL
a	NULL
functional	NULL
homeobox	NULL
domain	NULL
.	NULL

Cell	NULL
55:135-144	NULL
.	NULL

Landolfi	NULL
,	NULL
N.	NULL
F.	NULL
,	NULL
J.	NULL
D.	NULL
Capra	NULL
,	NULL
and	NULL
P.	NULL
W.	NULL
Tucker	NULL
.	NULL

1987	NULL
.	NULL

Protein-nucleotide	NULL
contacts	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
promoter	NULL
region	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:3851-3855	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
W.	NULL
Pierce	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

Protein-binding	NULL
sites	NULL
in	NULL
Ig	NULL
gene	NULL
enhancers	NULL
determine	NULL
transcriptional	NULL
activity	NULL
and	NULL
inducibility	NULL
.	NULL

Science	NULL
236:1573-1577	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
L.	NULL
Staudt	NULL
,	NULL
P.	NULL
Robbins	NULL
,	NULL
A.	NULL
Kuang	NULL
,	NULL
R.	NULL
C.	NULL
Mulligan	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

Repression	NULL
of	NULL
the	NULL
IgH	NULL
enhancer	NULL
in	NULL
teratocarcinoma	NULL
cellls	NULL
associated	NULL
with	NULL
a	NULL
novel	NULL
octamer	NULL
factor	NULL
.	NULL

Science	NULL
243:544-546	NULL
.	NULL

Margin	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Ares	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Weiner	NULL
.	NULL

1986	NULL
.	NULL

Human	NULL
U2	NULL
small	NULL
nuclear	NULL
RNA	NULL
genes	NULL
contain	NULL
an	NULL
upstream	NULL
enhancer	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:987-995	NULL
.	NULL

Mason	NULL
,	NULL
J.	NULL
O.	NULL
,	NULL
G.	NULL
T.	NULL
Williams	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Neuberger	NULL
.	NULL

1985	NULL
.	NULL

Transcription	NULL
cell	NULL
type	NULL
specificity	NULL
is	NULL
conferred	NULL
by	NULL
an	NULL
immunoglobulin	NULL
V	NULL
,	NULL
,	NULL
;	NULL
gene	NULL
promoter	NULL
that	NULL
encodes	NULL
a	NULL
functional	NULL
consensus	NULL
sequence	NULL
.	NULL

Cell	NULL
41:479-487	NULL
.	NULL

Mattaj	NULL
,	NULL
I.	NULL
W.	NULL
,	NULL
S.	NULL
Lienhard	NULL
,	NULL
J.	NULL
Jiricny	NULL
,	NULL
and	NULL
E.	NULL
M.	NULL
de	NULL
Robertis	NULL
.	NULL

1985	NULL
.	NULL

An	NULL
enhancer-like	NULL
sequence	NULL
within	NULL
the	NULL
Xenopus	NULL
U2	NULL
gene	NULL
promoter	NULL
facilitates	NULL
the	NULL
formation	NULL
of	NULL
stable	NULL
transcription	NULL
com-plexes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
316:163-167	NULL
.	NULL

Maxam	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
and	NULL
W.	NULL
Gilbert	NULL
.	NULL

1980	NULL
.	NULL

Sequencing	NULL
end-labeled	NULL
DNA	NULL
with	NULL
base-specific	NULL
chemical	NULL
cleavages	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

65:499-560	NULL
.	NULL

Meyer	NULL
,	NULL
K.	NULL
B.	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Neuberger	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
immunoglobulin	NULL
x	NULL
locus	NULL
contains	NULL
a	NULL
second	NULL
,	NULL
stronger	NULL
B	NULL
cell-specific	NULL
enhancer	NULL
which	NULL
is	NULL
located	NULL
downstream	NULL
of	NULL
the	NULL
contrast	NULL
region	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1959-1964	NULL
.	NULL

Murre	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
S.	NULL
McCaw	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
new	NULL
DNA	NULL
binding	NULL
and	NULL
dimerization	NULL
motif	NULL
in	NULL
immunoglobulin	NULL
enhancer	NULL
binding	NULL
,	NULL
daughterless	NULL
,	NULL
MyoD	NULL
,	NULL
and	NULL
myc	NULL
proteins	NULL
.	NULL

Cell	NULL
56:777-783	NULL
.	NULL

Nelsen	NULL
,	NULL
B.	NULL
,	NULL
T.	NULL
Kadesch	NULL
,	NULL
and	NULL
R.	NULL
Sen.	NULL
1990	NULL
.	NULL

Complex	NULL
regulation	NULL
of	NULL
the	NULL
immunoglobulin	NULL
m	NULL
heavy-chain	NULL
gene	NULL
enhancer	NULL
:	NULL
pB	NULL
,	NULL
a	NULL
new	NULL
determinant	NULL
of	NULL
enhancer	NULL
function	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:3145-3154	NULL
.	NULL

Parslow	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
D.	NULL
L.	NULL
Blair	NULL
,	NULL
W.	NULL
J.	NULL
Murphy	NULL
,	NULL
and	NULL
D.	NULL
K.	NULL
Granner	NULL
.	NULL

1984	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
5'-ends	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
;	NULL
a	NULL
novel	NULL
conserved	NULL
sequence	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:2650-2654	NULL
.	NULL

Parslow	NULL
,	NULL
T.	NULL
G.	NULL
,	NULL
S.	NULL
D.	NULL
Jones	NULL
,	NULL
B	NULL
.	NULL

Bond	NULL
,	NULL
and	NULL
K.	NULL
R.	NULL
Yamamoto	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
immunoglobulin	NULL
octanucleotide	NULL
:	NULL
independent	NULL
activity	NULL
and	NULL
selective	NULL
interaction	NULL
with	NULL
enhancers	NULL
.	NULL

Science	NULL
235:1498-1501	NULL
.	NULL

Perez-Mutul	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Macchi	NULL
,	NULL
and	NULL
B.	NULL
Wasylyk	NULL
.	NULL

1988	NULL
.	NULL

Mutational	NULL
28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

analysis	NULL
of	NULL
the	NULL
contribution	NULL
of	NULL
sequence	NULL
motifs	NULL
within	NULL
the	NULL
IgH	NULL
enhancer	NULL
to	NULL
tissue	NULL
specific	NULL
transcriptional	NULL
activation	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:6085-6096	NULL
.	NULL

Peterson	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
and	NULL
K.	NULL
L.	NULL
Calame	NULL
.	NULL

1987	NULL
.	NULL

Complex	NULL
protein	NULL
binding	NULL
within	NULL
the	NULL
mouse	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:4194-4203	NULL
.	NULL

Pierce	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
M.	NULL
Lenardo	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Oligonucleotide	NULL
that	NULL
binds	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
acts	NULL
as	NULL
a	NULL
lymphoid-specific	NULL
and	NULL
inducible	NULL
enhancer	NULL
element	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:1482-1486	NULL
.	NULL

Scheuermann	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
U.	NULL
Chen	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
developmental-specific	NULL
factor	NULL
binds	NULL
to	NULL
repressor	NULL
sites	NULL
flanking	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1255-1266	NULL
.	NULL

Schlokat	NULL
,	NULL
U.	NULL
,	NULL
D.	NULL
Bohmannn	NULL
,	NULL
H.	NULL
Schoeler	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1986	NULL
.	NULL

Nuclear	NULL
factors	NULL
binding	NULL
specific	NULL
sequences	NULL
within	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
interact	NULL
differentially	NULL
with	NULL
other	NULL
enhancer	NULL
elements	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:3251-3258	NULL
.	NULL

Schoeler	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1984	NULL
.	NULL

Specific	NULL
interaction	NULL
between	NULL
enhancer-containing	NULL
molecules	NULL
and	NULL
cellular	NULL
components	NULL
.	NULL

Cell	NULL
36:403-411	NULL
.	NULL

Schoeler	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
A.	NULL
K.	NULL
Hatzopoulos	NULL
,	NULL
R.	NULL
Balling	NULL
,	NULL
N.	NULL
Suzuki	NULL
,	NULL
and	NULL
P.	NULL
Gruss	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
family	NULL
of	NULL
octamer-specific	NULL
proteins	NULL
present	NULL
during	NULL
mouse	NULL
embryogenesis	NULL
:	NULL
evidence	NULL
for	NULL
germline-specific	NULL
expression	NULL
of	NULL
an	NULL
Oct	NULL
factor	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:2543-2550	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Multiple	NULL
nuclear	NULL
factors	NULL
interact	NULL
with	NULL
the	NULL
immunoglobulin	NULL
enhancer	NULL
sequences	NULL
.	NULL

Cell	NULL
46:705-716	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

Factors	NULL
regulating	NULL
immunoglo-bulin-gene	NULL
transcription	NULL
,	NULL
p.	NULL
327-344	NULL
.	NULL

In	NULL
T.	NULL
Honjo	NULL
,	NULL
F.	NULL
W.	NULL
Alt	NULL
,	NULL
and	NULL
T.	NULL
H.	NULL
Rabbitts	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Immunoglobulin	NULL
genes	NULL
.	NULL

Academic	NULL
Press	NULL
,	NULL
London	NULL
.	NULL

Singh	NULL
,	NULL
H.	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
P.	NULL
Sharp	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
nuclear	NULL
factor	NULL
that	NULL
binds	NULL
a	NULL
conserved	NULL
sequence	NULL
motif	NULL
in	NULL
transcriptional	NULL
control	NULL
elements	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
319:154-158	NULL
.	NULL

Sive	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1986	NULL
.	NULL

The	NULL
interaction	NULL
of	NULL
a	NULL
common	NULL
factor	NULL
with	NULL
conserved	NULL
promoter	NULL
and	NULL
enhancer	NULL
sequences	NULL
in	NULL
histone	NULL
H2b	NULL
,	NULL
immunoglobulin	NULL
and	NULL
U2	NULL
small	NULL
nuclear	NULL
(	NULL
sn	NULL
)	NULL
RNA	NULL
genes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:6382-6386	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
R.	NULL
G.	NULL
Clerc	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
J.	NULL
H.	NULL
LeBowitz	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Molecular	NULL
cloning	NULL
of	NULL
a	NULL
lymphoid-specific	NULL
cDNA	NULL
encoding	NULL
a	NULL
protein	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
regulatory	NULL
octamer	NULL
DNA	NULL
motif	NULL
.	NULL

Science	NULL
241:577-580	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
T.	NULL
Wirth	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
lymphoid-specific	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
octamer	NULL
motif	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323	NULL
:	NULL
640-643.	NULL
.	NULL

Stewart	NULL
,	NULL
G.	NULL
S.	NULL
A	NULL
.	NULL

B.	NULL
,	NULL
S.	NULL
Dovey	NULL
,	NULL
and	NULL
D.	NULL
M.	NULL
O'Rourke	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
rapid	NULL
method	NULL
for	NULL
site	NULL
directed	NULL
mutagenesis	NULL
of	NULL
plasmid	NULL
DNA	NULL
.	NULL

BioTechniques	NULL
6:511-518	NULL
.	NULL

Sturm	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
G.	NULL
Das	NULL
,	NULL
and	NULL
W.	NULL
Herr	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
ubiquitous	NULL
octamer	NULL
binding	NULL
protein	NULL
Oct-1	NULL
contains	NULL
a	NULL
Pou	NULL
domain	NULL
with	NULL
a	NULL
homeo	NULL
box	NULL
subdomain	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:1582-1599	NULL
.	NULL

Tsao	NULL
,	NULL
B.	NULL
P.	NULL
,	NULL
X.-F.	NULL
Wang	NULL
,	NULL
C.	NULL
L.	NULL
Peterson	NULL
,	NULL
and	NULL
K.	NULL
Calame	NULL
.	NULL

1988	NULL
.	NULL

In	NULL
vivo	NULL
functional	NULL
analysis	NULL
of	NULL
in	NULL
vitro	NULL
protein	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy	NULL
chain	NULL
enhancer	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:3239-3253	NULL
.	NULL

Weinberger	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
P.	NULL
Sharp	NULL
.	NULL

1986	NULL
.	NULL

Distinct	NULL
factors	NULL
bind	NULL
to	NULL
apparently	NULL
homologous	NULL
sequences	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
322:846-847.	NULL
.	NULL

Weinberger	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
S.	NULL
Jat	NULL
,	NULL
and	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
.	NULL

1988	NULL
.	NULL

Localization	NULL
of	NULL
a	NULL
repressive	NULL
sequence	NULL
contributing	NULL
to	NULL
B-cell	NULL
specificity	NULL
in	NULL
the	NULL
immunoglobulin	NULL
heavy-chain	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:988-992	NULL
.	NULL

Wirth	NULL
,	NULL
T.	NULL
,	NULL
L.	NULL
Staudt	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
octamer	NULL
oligonucleotide	NULL
upstream	NULL
of	NULL
a	NULL
TATA	NULL
motif	NULL
is	NULL
sufficient	NULL
for	NULL
lymphoid-specific	NULL
promoter	NULL
activity	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
329:174-177	NULL
.	NULL

